Topical Medication Therapy for Glaucoma and Ocular Hypertension

Tao Wang¹, Linlin Cao², Qikun Jiang¹* and Tianhong Zhang¹*  

¹Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China,  
²Department of Pharmaceutics, The Second Hospital of Dalian Medical University, Dalian, China

Glaucoma is one of the most common causes of blindness, thus seriously affecting people’s health and quality of life. The topical medical therapy is as the first line treatment in the management of glaucoma since it is inexpensive, convenient, effective, and safe. This review summarizes and compares extensive clinical trials on the topical medications for the treatment of glaucoma, including topical monotherapy agents, topical fixed-combination agents, topical non-fixed combination agents, and their composition, mechanism of action, efficacy, and adverse effects, which will provide reference for optimal choice of clinical medication. Fixed-combination therapeutics offer greater efficacy, reliable security, clinical compliance, and tolerance than non-fixed combination agents and monotherapy agents, which will become a prefer option for the treatment of glaucoma. Meanwhile, we also discuss new trends in the field of new fixed combinations of medications, which may better control IOP and treat glaucoma.

Keywords: glaucoma, monotherapy, fixed combination therapy, non-fixed combination therapy, intraocular pressure, adverse effects

1 INTRODUCTION

Glaucoma is a neurodegenerative ophthalmologic disease characterized by the progressive degeneration of the retinal ganglion cells and axonal death, resulting in an irreversible blindness (Marshall et al., 2018; Garcia-Medina et al., 2020). Glaucoma is commonly related to high intraocular pressure (IOP) with a subsequent injury of the optic nerve, and eventually blindness (Goel et al., 2010). The normal physiological IOP is 5–20 mmHg, which in turn depends on the adjustment of production and absorption of the aqueous humor (AH) (Goel et al., 2010; Skrzypecki et al., 2018). The ciliary muscle produces the AH that leaves the eye by passive flows through two pathways: the conventional (trabecular meshwork, TM) and unconventional (uveoscleral) pathway (Huang et al., 2018). Normal tension glaucoma (NTG) is characterized by a IOP usually below 21 mmHg, while the primary open-angle glaucoma (POAG) has a IOP of over 22 mmHg (Razeghinejad and Lee, 2019), the latter being the main and modifiable risk factor for glaucoma and its progression (Fogagnolo and Rossetti, 2011; Jayaram, 2020). Ocular hypertension (OHT) is defined as a IOP over 21 mmHg without the damage of the optic disk and view field (Chamard et al., 2020), but it is most likely to develop into open-angle glaucoma (OAG) (Kass et al., 2021).

Currently, the treatments to cure glaucoma mainly consist of surgical intervention and topical medication therapy (Guglielmi et al., 2019; Webb, 2021). Surgical intervention is required when a patient’s visual independence is at risk (Lusthaus and Goldberg, 2019). The risks associated with the surgical procedure and the postoperative recovery are complicated with each patient and the cost is relatively expensive (Razeghinejad and Lee, 2019). Therefore, topical medication therapy with reliable effectiveness and safety is often as the preferred approach in the management of glaucoma (Conlon et al., 2017; Guglielmi et al., 2019; Webb, 2021). The classes of topical monotherapy
medications to cure glaucoma include prostaglandin analogs, rho-kinase inhibitors, β-adrenergic blocking agents, α-2 adrenergic agonists, and carbonic anhydrase inhibitors, but they are often inadequate to keep IOP under control (Schehelein et al., 2017). Therefore, the combination of multiple medications is significantly necessary for an adequate control of IOP.

The lowering effect of IOP by the fixed combination and non-fixed combination medications are similar and both the combinations are superior to their constituent agents. Importantly, the fixed combination and non-fixed combination medications have reliable security with no additional new side effects comparing to monotherapy agents. Fixed combination medications have a greater

---

**TABLE 1** The class and list of Prostaglandin Analogs.

| Mode of action                  | Mechanism                          | Drug                          | IOP reduction | Current market status | Usage, dosage | Side effects (ocular)                                      |
|--------------------------------|------------------------------------|-------------------------------|---------------|-----------------------|---------------|-----------------------------------------------------------|
| F2 receptor agonists           | Increasing uveoscleral outflow      | Latanoprost                   | 25–33%        | On the market         | Once daily    | Conjunctival hyperaemia; Eyelash lengthening; Prostaglandin-associated; Periorbitopathy |
|                                |                                    | Bimatoprost                   |               |                       |               |                                                           |
|                                |                                    | Travoprost                    |               |                       |               |                                                           |
|                                |                                    | Tafluprost                    |               |                       |               |                                                           |
| E2-EP2 receptor dual agonists  | Increasing uveoscleral outflow      | Omidenepag isopropyl          | 10–15%        | On the market         | Once daily    |                                                           |
|                                |                                    | Aganepag isopropyl AGN-210669| 25–33%        | Phase II              |               |                                                           |
| E2-EP3-F2-receptor three agonists | Increasing uveoscleral outflow       | Sepetaprost                   | 27–30%        | Phase II              | Once daily    |                                                           |
| Nitric-oxide donating F2 receptor agonists | Increasing uveoscleral outflow; Increasing trabecular outflow | Latanoprostene bunod NCX 470 | 32–34%        | Phase III             |               |                                                           |
convenience, compliance, and tolerance than non-fixed combination medications, since they can decrease dosing frequency and eliminate the washout effect by decreasing the number of instilled drops, the total number of bottles of medication in use, and the exposure to preservatives (Babic, 2015).

This review collects and compares extensive clinical trials on the topical anti-glaucoma medications, and summarized their

| TABLE 2 | The class and list of Rho-kinase inhibitors. |
|---------|---------------------------------------------|
| Drug    | IOP reduction | Current market status | Usage, dosage | Mechanism | Side effects (ocular) | Side effects (systematic) |
| Ripasudil | 16–20% | On the market | Twice daily | Increasing trabecular outflow; Decreasing episcleral venous pressure; Reducing aqueous humour formation | Conjunctival hyperemia; Conjunctival hemorrhage; Cornea verticillata; Eye pruritus; Instillation site pain; Increased lacrimation |
| Netarsudil | — | On the market | Once daily | — | — |
| RKI-983/SNJ-1656/Y-39983 | — | Phase II | Twice daily | — | — |
| AMA-0076/PHP-201 | — | Phase II | Two or three times daily | — | — |
| Y-27632 | — | Preclinical | — | — | — |

| TABLE 3 | The class and list of β blocking agents. |
|---------|---------------------------------------------|
| Mode of action | Drug | IOP reduction | Current market status | Usage, dosage | Mechanism | Side effects (ocular) | Side effects (systematic) |
| Nonselective β blocking agents | Timolol | 27–35% | On the market | Twice daily | Reducing aqueous humour formation | Conjunctival hyperemia; Ocular surface discomfort; Reduction in tear flow | Bradycardia; Heart block; Arrhythmia; Bronchospasm; Worsening of underlying asthma or chronic obstructive pulmonary disease |
| Carteolol | — | — | — | — | — |
| Selective β-1 blocking agents | Betaxolol | 18–26% | On the market | Twice daily | Reducing aqueous humour formation | Conjunctival hyperemia; Ocular surface discomfort; Reduction in tear flow | Bradycardia; Heart block; Arrhythmia; Bronchospasm; Worsening of underlying asthma or chronic obstructive pulmonary disease |
| Bamosiran | — | Phase II | Once daily | — | — |

| TABLE 4 | The class and list of other topical glaucoma monotherapy. |
|---------|---------------------------------------------|
| Class | Drug | IOP reduction | Current market status | Usage, dosage | Mechanism | Side effects (ocular) | Side effects (systematic) |
| α-2 adrenergic agonists | Brimonidine tartrate | 20–27% | On the market | Three times daily | Increasing uveoscleral and trabecular outflow; Reducing aqueous humour formation | Beipharitis; Beipharoconjunctivitis; Conjunctivitis; Conjunctival follicles; Mild hyperemia; Staining of the cornea; Blurred vision; Foreign body sensation | — |
| Carbonic anhydrase inhibitors | Systemic inhibitors: acetazolamide, methazolamide, dichlorophenamide | 25–30% | On the market | Twice daily | Reducing aqueous humour formation | Conjunctival hyperemia; Ocular surface discomfort; Reduction in tear flow | Numbness and tingling of extremities; Metallic taste; Depression; Fatigue; Malaise; Weight loss; Decreased libido; Gastrointestinal irritation; Metabolic acidosis; Renal calculi; Transient myopia | — |
| Topical inhibitors: Dorzolamide, Brinzolamide | 15–25% | On the market | Two or three times daily | Decreasing aqueous humour formation | Conjunctival hyperemia; Ocular surface discomfort; Reduction in tear flow | Pruritus; Bitter taste | — |
| Adenosine receptor agonists | Trabodenoson | — | Discontinued | Two or three times daily | Increasing trabecular outflow | Conjunctival hyperemia; Ocular surface discomfort; Reduction in tear flow | Pruritus; Bitter taste | — |

Frontiers in Pharmacology | www.frontiersin.org 3 December 2021 | Volume 12 | Article 749858
TABLE 5 | The class and list of fixed-combination medications.

| Classes                                         | Medications              | IOP reduction | Current market status | Usage, dosage | Mechanism                                           |
|------------------------------------------------|--------------------------|---------------|-----------------------|---------------|----------------------------------------------------|
| Prostaglandin analogs and β-blockers           | Latanoprost/Timolol      | 32–38%        | On the market          | Once daily    | Increasing uveoscleral outflow; Reducing aqueous humour formation |
|                                                | Bimatoprost/Timolol      |               |                        |               |                                                    |
|                                                | Travoprost/Timolol       |               |                        |               |                                                    |
|                                                | Tafluprost/Timolol       |               |                        |               |                                                    |
|                                                | Latanoprost/cartolol     |               |                        |               |                                                    |
| Prostaglandin analogs and Rhokinase inhibitors| Latanoprost/Netarsudil   | 31–37%        | On the market          | Once daily    | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| Prostaglandin analogs and α-2 adrenergic agonists | Bimatoprost/Brimonidine | 25–33%        | Phase II               | Once daily    | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| Prostaglandin analogs and Carbonic anhydrase inhibitor | Travoprost/Brinzolamide | 25–33%        | Phase III              | Twice daily   | Increasing uveoscleral outflow; Reducing aqueous humour formation |
|                                                | Latanoprost/Brinzolamide | —             | Phase II               |               |                                                    |
| β-blockers and α-2 adrenergic agonists          | Timolol/Brimonidine      | 28–34%        | On the market          | Twice daily   | Increasing uveoscleral and trabecular outflow; Reducing aqueous humour formation |
| β-blockers and Carbonic anhydrase inhibitors    | Timolol/Brinzolamide     | 28–35%        | On the market          | Twice daily   | Reducing aqueous humour formation                  |
| α-2 adrenergic agonists and Carbonic anhydrase inhibitors | Brinzolamide/Brimonidine | 21–35%        | On the market          | Three times daily | Increasing uveoscleral outflow; Reducing aqueous humour formation |
|                                                | Brinzolamide/Brimonidine | —             | Phase III              |               | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| Prostaglandin analogs and β-blockers and α-2 agonists | Bimatoprost/Timolol/Brimonidine | — | Phase III              | Twice daily   | Increasing uveoscleral outflow; Reducing aqueous humour formation |
| β-blockers and α-2 agonists and Carbonic anhydrase inhibitors | Dorzolamide/Brimonidine | —             | On the market          | Twice daily   | Increasing uveoscleral outflow; Reducing aqueous humour formation |

mechanism of action, efficacy, adverse effects (AEs), and safety on Tables 1–6. And the structure of this review is shown on Figure 1.

2 METHODS

This review summarizes the effectiveness and safety of topical anti-glaucoma agents based on an overall review of related literatures published. Extensive references were obtained by searching keywords: prostaglandin analogs, rhokinase inhibitors, β-adrenergic blocking agents, α-2 adrenergic agonists, carbonic anhydrase inhibitors, fixed-combination agents, glaucoma and so on. Systematic and large-scale clinical trials, meta-analysis and review articles were the main priority; because of the lacking of related articles, small-scale experiments and related cases were referenced. The main clinical trials more elaborated were summarize on Table 6.

3 TOPICAL MONOTHERAPY AGENTS

3.1 Prostaglandin Analogs (PGAs)

Prostaglandins (PGs) are potent biologically active metabolites of the arachidonic acid that modulate many biological responses in various tissues including the eye (Matsou and Anastasopoulos, 2018). PGAs represent the first-line medical therapy to cure POAG and OHT, since they target different PG receptors to reduce IOP (Diaconita et al., 2018; Angeli and Supuran, 2019) (Table 1).

3.1.1 Prostaglandin F2-Alpha Receptor Agonists

Prostaglandin F2 (PGF2) analogs bind to PG receptors and promote muscle relaxation and extracellular matrix remodeling in the ciliary muscle and TM, thus increasing AH outflow in both the conventional and unconventional pathways (Matsou and Anastasopoulos, 2018; Jayanetti et al., 2020). PGF2 analogs reduce IOP by 25–33% (Diaconita et al., 2018), they are widely available on the market in most countries (Matsou and Anastasopoulos, 2018), and include latanoprost (Xalatan®), bimatoprost (Lumigan®), travoprost (Travatan Z®), and tafluprost (Tapros®) (Matsou and Anastasopoulos, 2018).

PGF2 analogs exert different IOP lowering effects, as demonstrated by clinical trials and meta-analysis: bimatoprost exerts the greatest IOP lowering effect and the highest incidence of hyperemia than other PGF2 analogs (Aptel and Denis, 2011; Yu and Welge-Lussen, 2013; Takagi et al., 2018). In addition, they are well tolerated and induce mild AEs including conjunctival hyperemia, increase in the eyelash growth, as well as changes in periocular pigmentation and iris color (Aptel and Denis, 2011; Yu and Welge-Lussen, 2013).

3.1.2 Prostaglandin E2 Receptor Agonists

Prostaglandin E2 (PGE2) has high affinity for four different E-type prostaglandin (EP1-4) receptors (Matsou and
| First author/Year/ References | Study design | Evaluation period | Diagnosis | Glaucoma medications | Mean baseline IOP (mmHg) | Post treatment IOP (mmHg) | Adverse effects | Comments |
|-------------------------------|-------------|------------------|-----------|----------------------|--------------------------|--------------------------|---------------|----------|
| Suzuki et al. (2018)         | prospective, observer-masked, randomized study | 28 days | POAG | BIT-FC (18); LT-FC (14); TrT-FC (18) | 13.5 ± 4.2 mmHg | Mean 24-h IOP BIT-FC: 14.6 ± 2.9 mmHg; LT-FC: 14.1 ± 3.7 mmHg; TrT-FC: 15.8 ± 2.0 mmHg Mean diurnal IOP variation BIT-FC: 4.6 ± 2.3 mmHg; LT-FC: 5.8 ± 2.4 mmHg; TrT-FC: 4.3 ± 1.7 mmHg Mean nocturnal IOP variation BIT-FC: 3.2 ± 2.8 mmHg; LT-FC: 2.9 ± 1.9 mmHg; TrT-FC: 3.0 ± 1.6 mmHg | — | All three fixed combinations effectively controlled IOP for 24-h and had a similar effect on diurnal and nocturnal IOP variations |
| Shoji et al. (2013)           | multicenter, prospective, randomized, single-blinded, crossover clinical trial | 24 weeks with cross over at 12 weeks | NTG | LT-FC (30); TrT-FC (30) | 14.8 ± 3.3 mmHg | Mean 24-h IOP (12 weeks) BIT-FC: 13.8 ± 3.9 mmHg; LT-FC: 12.4 ± 2.90 mmHg Mean IOP change (24 weeks) LT-FC: 1.1 ± 1.3 mmHg; TrT-FC: 2.4 ± 1.3 mmHg | Burning eye sensation, Mild superficial punctate keratitis, Skin pigmentation: LT-FC: 5.1, 5.1, 1.7%; TrT-FC: 1.7, 1.7, 5.1% | The additional reduction in IOP was greater with TrT-FC than with LT-FC, and their tolerability profiles were similar |
| Eren et al. (2012)            | randomized, double-blind, crossover study | 6 weeks | (33) OAG | LT-FC; DzT-FC | 25.09 ± 2.8 mmHg | Mean diurnal IOP LT-FC: 16.3 mmHg DzT-FC: 17.3 mmHg The peak IOP LT-FC: 18.5 mmHg DzT-FC: 19.9 mmHg Mean diurnal range LT-FC: 4.4 ± 2.2 mmHg; DzT-FC: 4.6 ± 2.2 mmHg | Bitter taste, Imitation and stinging, Conjunctival hyperemia, Superficial punctate keratitis (case): LT-FC: 0, 1, 2, 1; DzT-FC: 7, 1, 1, 2 | Mean diurnal IOP and peak IOP were lower with LT-FC than with DzT-FC. DzT-FC group had significant side effects of stinging and bitter taste |
| Hoemmer et al. (2012)        | randomized, double-masked, 2-way crossover design study | 6 weeks | (18) OAG | LT-FC | 25.3 ± 2.8 mmHg | The percent of IOP reduction LT-FC: 35.0-10.0%; BrT-FC: 33.6-8.8% | — | LT-FC and BiT-FC had equally effective in reducing IOP, |
| Shim et al. (2014)           | prospective, clinical study | 24 h | healthy subjects | LT-FC (30); BIT-FC (28) | LT-FC: 11.18 ± 3.27 mmHg (treated eye), 11.36 ± 3.07 mmHg (untreated eye); BIT-FC: 13.00 ± 2.12 mmHg (treated eye), 12.60 ± 2.09 mmHg (untreated eye) | The largest difference in IOP (between treated and untreated eyes) LT-FC: 1.93 mmHg (10 h after installation) BIT-FC: 1.67 mmHg (8 h after installation) | Conjunctival hyperemia, Foreign-body sensation, Superficial punctate epithelopathy LT-FC: 25, 17.9, 10.7%; BiT-FC: 10, 20, 13.3% | LT-FC and BiT-FC provided a significant reduction in IOP from baseline with no significantly difference in side effects |
| Konstas et al. (2014)        | prospective, observer-masked, active controlled, cross-over, comparison study | 3 months | OAG | LT-FC (20); PF-TrT-FC (22) | 21.5 ± 1.6 mmHg | Mean 24-h IOP LT-FC: 19.3 ± 2.3 mmHg; PF-TrT-FC: 18.9 ± 2.2 mmHg Mean diurnal IOP changes LT-FC: −8.66 mmHg; LT-NC: −8.96 mmHg | Tear film break-up time, Corneal stain, Schrimer I test LT-FC: 4.65 s, 1.8 s, 9.2 mm PF-TrT-FC: 5.15 s, 1.5 s, 9.9 mm | The mean 24-h IOP lowering of TrT-FC was statistically more significant compared to LT-FC in patients |
| Zhao et al. (2011)           | randomized, open-label, parallel-group, noninferiority study | 8 weeks | OAG, OHT | LT-FC (125); LT-nFC (125) | LT-FC: 25.8 mmHg; LT-nFC: 26.0 mmHg | Mean diurnal IOP (8 weeks, 12 weeks) LT-FC: 17.9 (3.3), 17.8 (3.5) mmHg; Latanoprost: 18.9 (2.9), 19.3 (3.4) mmHg Timolol: 20.9 (3.7), 20.9 (3.5) mmHg | The incidence of AEs: LT-FC: 11.2%, LT-nFC: 6.5%; Conjunctival hyperemia: LT-FC: 7.2%, LT-nFC: 4.8% The incidence of ocular-related AEs: LT-FC: 17.8%, Latanoprost: 23.9%, Timolol: 15.7%; Conjunctival hyperemia: LT-FC: 7.0%, Latanoprost: 10.4%, Timolol: 3.1% | The fixed combination of latanoprost and timolol was as effective as the non-fixed combination LT-FC therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol |
| Higginbotham et al. (2010)   | randomized, double-masked, parallel-group study | 12 weeks | OAG, OHT | LT-FC (129); Latanoprost (134); Timolol (131) | LT-FC: 28.0 (2.2) mmHg; Latanoprost: 28.2 (2.2) mmHg; Timolol: 28.1 (2.3) mmHg | Mean diurnal IOP (6 weeks, 12 weeks) LT-FC: 19.7 (3.3), 17.8 (3.5) mmHg Latanoprost: 18.9 (2.9), 19.3 (3.4) mmHg Timolol: 20.9 (3.7), 20.9 (3.5) mmHg | Mean diurnal IOP reductions from baseline (12 weeks) LT-FC: 73.5%; Latanoprost: 57.5% | (Continued on following page) |
TABLE 6 | (Continued) A summary of clinical trials comparing different fixed combination and non-fixed combination agents.

| First author/Year/References | Study design | Evaluation period | Diagnosis | Glaucoma medications | Mean baseline IOP (mmHg) | Post treatment IOP (mmHg) | Adverse effects | Comments |
|------------------------------|--------------|-------------------|-----------|----------------------|-------------------------|---------------------------|----------------|----------|
| Asrani et al. (2019)         | randomized, double masked, phase 3 clinical trial | 3 months | OAG, OHT | NL-FC (238); Latanoprost (236); Netarsudil (244) | 22.4–24.8 mmHg | Timolol: 32.8% | Mean percent of diurnal IOP changes: NL-FC: -33.7%, Latanoprost: -27.6%, Netarsudil: -22.8% | Conjunctival hyperemia NL-FC: 63.0%, Latanoprost: 62.5%, Netarsudil: 64.1% | NL-FC provided clinically and statistically significantly greater IOP-lowering effect than monotherapy. The incidence rate of conjunctival hyperemia significant increases, but it is acceptable |
| Asrani et al. (2020)         | Phase 3 clinical trial | 3 months | OAG, OHT | NL-FC (463); Latanoprost (460); Netarsudil (490) | 23.6 mmHg; 23.5 mmHg; 23.6 mmHg | Mean diurnal IOP: NL-FC: 15.8 mmHg, Latanoprost: 17.3 mmHg, Netarsudil: 18.4 mmHg; The percent of IOP reduction >40%: NL-FC: 30.9%, Latanoprost: 8.5%, Netarsudil: 5.9% | The mean 24-h IOP reduction: BIT-FC: 12.2 mmHg (39.2%), Latanoprost: 9.9 mmHg (31.9%); The mean 24-h IOP fluctuation: BIT-FC: 3.8 mmHg, Latanoprost: 4.2 mmHg | Comparing to latanoprost, BIT-FC had a better IOP-lowering effect. However, both medications had no difference in mean 24-h IOP fluctuation |
| Konstas et al. (2013b)       | prospective, observer-masked, crossover, uncontrolled protocol | 3 months | high-pressure exfoliation syndrome (glaucoma) | BIT-FC (21); latanoprost (20) | 31.1 mmHg | The mean 24-h IOP reduction: BIT-FC: 12.2 mmHg (39.2%), Latanoprost: 9.9 mmHg (31.9%); The mean 24-h IOP fluctuation: BIT-FC: 3.8 mmHg, Latanoprost: 4.2 mmHg | The percent of treatment-related AEs appeared in BIT-FC: 48.0%, Bimatoprost: 60.0%, Timolol: 31.6%, Conjunctival hyperemia BIT-FC: 25.7%, Bimatoprost: 43.4%, Timolol: 8.7% | BIT-FC provided statistically significant greater reduction in IOP over the 12-months than bimatoprost and timolol monotherapies. And there is no addition AEs appeared in BIT-FC group |
| Lewis et al. (2010)          | identical, double-masked, parallel studies | 12 months | OHT | BIT-FC (533); Bimatoprost (n = 265); Timolol (n = 263) | 23.3–26.2 mmHg | Mean diurnal IOP reduction: BIT-FC: 7.7 mmHg; Bimatoprost: 7.6 mmHg; Timolol: 6.4 mmHg; The percent of IOP <18 mmHg: BIT-FC: 23.3%, Bimatoprost: 18.1%, Timolol: 8.0% | The average diurnal IOP change: PF-TFT-FC: -8.55 mmHg (32%); Timolol: -7.35 mmHg (28%); The average diurnal IOP change: PF-TFT-FC: -8.61 mmHg (33%); Timolol: -7.23 mmHg (28%) | Conjunctional/ocular hyperemia: PF-TFT-FC: 9.5%, Timolol: 0% |
| Pfeiffer et al. (2014)       | stratified, double-masked, randomized, multicenter phase III study | 3 months | OAG, OHT (prior timolol users) | PF-TFT-FC (96); Timolol (94) | – | The average diurnal IOP change: PF-TFT-FC: -8.55 mmHg (32%); Timolol: -7.35 mmHg (28%); The average diurnal IOP change: PF-TFT-FC: -8.61 mmHg (33%); Timolol: -7.23 mmHg (28%) | The average diurnal IOP change: PF-TFT-FC: -8.55 mmHg (32%); Timolol: -7.35 mmHg (28%); The average diurnal IOP change: PF-TFT-FC: -8.61 mmHg (33%); Timolol: -7.23 mmHg (28%) | Conjunctional/ocular hyperemia: PF-TFT-FC: 9.5%, Timolol: 0% |
| Babic et al. (2013)          | randomized, controlled, open-label, prospective study | 3 months | POAG, OHT | TR-TFC (30); DzT-FC (26) | 25.10 mmHg; 24.23 mmHg | Mean IOP reduction: TR-TFC: 8.96 mmHg (38.28%), DzT-FC: 8.07 mmHg (35.66%) | The most frequent ocular AEs: TR-TFC group: hyperemia (50%), blurred vision and pruritus (8.7%); DzT-FC group: dry eye sensation (30.8%), foreign body sensation (23.1%) | Tr-TFC was slightly more effective than DzT-FC in reducing mean diurnal IOP. Both treatments were well tolerated and safe |
| Mckay, (2014)               | prospective, randomized, controlled, clinical study | 6 months | POAG | BIT-FC (40); Tr-Fc (40) | 23.00 mmHg; 24.00 mmHg | Mean IOP reduction: BIT-FC: 11.17 mmHg (45.5%); Tr-Fc: 7.89 mmHg (33.3%) | Ocular redness: BIT-FC: 10.0%, Tr-Fc: 12.5% | BIT-FC can provide more effective IOP reduction than Tr-Fc |
| Pfeiffer and group (2011)    | double-masked | 12 weeks | OAG, OHT | TrBz-nFC (90); TrBz-fNC (80) | 21.0 ± 2.2 mmHg; 21.2 ± 2.2 mmHg | Mean IOP reduction: TrBz-nFC: 3.2 ± 2.4 mmHg (14.8 ± 10.5%); TrBz-fNC: 4.2 ± 2.8 mmHg (19.6 ± 12.7%) | Conjunctional hyperemia: TrBz-nFC: 8.8%, TrBz-fNC: 5.4% | Timolol added to travoprost reduced IOP more effectively than brinzolamide added to travoprost | (Continued on following page)
### TABLE 6 | (Continued) A summary of clinical trials comparing different fixed combination and non-fixed combination agents.

| Study author/Year/ References | Study design | Evaluation period | Diagnosis | Glaucoma medications | Mean baseline IOP (mmHg) | Post treatment IOP (mmHg) | Adverse effects | Comments |
|--------------------------------|--------------|-------------------|-----------|----------------------|-------------------------|--------------------------|-----------------|----------|
| Yamamoto et al. (2016)         | randomized, controlled, phase 3 trials | 8 weeks | POAG, OHT, NTG | LC-FC (118); Latanoprost (119) | 20.1 ± 2.2 mmHg; 20.1 ± 1.9 mmHg | Mean IOP reduction: LC-FC: 2.9 mmHg; Latanoprost: 1.6 mmHg | The incidence of drug-related AEs: LC-FC: 6.8%; Latanoprost: 4.5% | Both LC-FC and LC-nFC had comparable effects and achieved a significantly greater IOP-lowering effect than latanoprost and carteolol |
| Kim et al. (2016)              | multi-institution, randomized, active-controlled, open-label, parallel-group study | 12 weeks | NTG | BrT-FC (48); Timolol (47) | 15.2 ± 3.42 mmHg; 14.58 ± 3.05 mmHg | Mean IOP reduction: BrT-FC: 11.87 ± 2.51 mmHg, Timolol: 12.76 ± 3.14 mmHg; The ratio of IOP reduction >20%: BrT-FC: 56%, Timolol: 23.53% | The incidence of ocular AEs: BrT-FC: 18.18%; Timolol: 5.45%; The incidence of systemic AEs: BrT-FC: 1.82%, Timolol: 3.64% | BrT-FC has a superior IOP-lowering effect than timolol in NTG patients, which also has well tolerated and safe |
| Katz et al. (2012)             | prospective, randomized, multicenter-investigator-masked clinical trial | 12 weeks | POAG, OHT | BrT-FC (73); Latanoprost (75) | 24.7 mmHg; 25.4 mmHg | The mean diurnal IOP: BrT-FC: 17.8 (2.9) mmHg, Latanoprost: 17.9 (3.9) mmHg; The mean change in diurnal IOP: BrT-FC: 7.0 mmHg (27.9%), Latanoprost: 7.5 mmHg (29.7%) | The incidence of AEs: BrT-FC: 21.9%; Latanoprost: 10.7%; Conjunctival hyperemia, Lid Edema: BrT-FC: 11.6%, 5.8%; Latanoprost: 16.0%, 1.3% | BrT-FC and latanoprost have similar efficacy in lowering IOP in patients with glaucoma or OHT over 12 weeks. AEs were more common in BrT-FC group, but none of the adverse events were serious |
| Gulikih et al. (2011)          | prospective study | 4 weeks | POAG | BrT-FC (42); DzT-FC (42) | 24.6 mmHg; 24.1 mmHg | The mean diurnal IOP: BrT-FC: 16.9 mmHg, DzT-FC: 17.3 mmHg | The Schirmer scores (tear function tests) (before and after): BrT-FC: 14.1 ± 2.2 and 13.2 ± 3.0 mm; DzT-FC: 13.3 ± 2.8, and 12.3 ± 3.8 mm; The tear break-up time (before and after): BrT-FC: 10.9 ± 1.9 and 9.9 ± 1.9 s, DzT-FC: 10.1 ± 1.8 and 9.1 ± 1.6 s; Burning, Foreign body sensation, Itching: BrT-FC: 19, 12, 14%; DzT-FC: 43, 28, 12% | Both BrT-FC and DzT-FC can effectively lower IOP. The side-effect profile is similar in both groups. BrT-FC reduces lesser occurrence of a burning sensation, which may improve patient compliance. Both groups significantly lower tear secretion and tear break-up time, which may lead to dry eye |
| Realini et al. (2013)          | identical, phase 3, randomized, clinical trials | 3 months | OAG, OHT | BzBr-FC (424); Brinzolamide (452); Brimonidine (448) | 23.7–27.0 mmHg; 23.9–27.2 mmHg; 23.7–27.2 mmHg | The mean diurnal IOP: BzBr-FC: 16.5–20.2 mmHg, Brinzolamide: 19.5–21.2 mmHg, Brimonidine: 18.0–22.5 mmHg | The incidence of serious AEs: BzBr-FC: 2.6%, Brinzolamide: 1.0%, Brimonidine: 1.7%; The incidence of discontinuation: BzBr-FC: 9.3%; Brinzolamide: 0.5%, Brimonidine: 7.4%; The incidence of treatment-related AEs: BzBr-FC: 28.5%, Brinzolamide: 11.5%, Brimonidine: 22.9% | BzBr-FC had significantly superior IOP-lowering activity compared with either brinzolamide or brimonidine alone and a safety profile consistent with that of its individual components |
| Aung et al. (2014)             | Phase 3, randomized, double-masked clinical trial | 6 months | OAG | BzBr-FC (193); Brinzolamide (150); Brimonidine (175) | 25.9 ± 0.19 mmHg; 25.9 ± 0.2 mmHg; 26.0 ± 0.19 mmHg | The mean diurnal IOP reduction (week-2, month-0 and month-6): BzBr-FC: 7.6, 7.9, 7.8 mmHg; Brinzolamide: 6.1, 6.5, 6.7 mmHg; Brimonidine: 6.0, 6.4, 6.4 mmHg | The incidence of serious AEs: BzBr-FC: 2.6%, Brinzolamide: 1.0%, Brimonidine: 1.7%; The incidence of discontinuation: BzBr-FC: 9.3%; Brinzolamide: 0.5%, Brimonidine: 7.4%; The incidence of treatment-related AEs: BzBr-FC: 28.5%, Brinzolamide: 11.5%, Brimonidine: 22.9% | BzBr-FC had a significantly greater IOP-lowering effect than either brinzolamide or brimonidine alone and displayed a safety profile consistent with its individual components |
| Katz et al. (2013)             | Phase 3, double-masked, parallel | 3 months | OAG, OHT | BzBr-FC (220); Brinzolamide (220); | 26.9–23.2 mmHg; 27.1–23.6 mmHg; 27.0–24.0 mmHg | The mean diurnal IOP reduction: BzBr-FC: 24.1–34.9%, | Vision blurred, Ocular hyperemia, Dry eye, Dysgeusia: BzBr-FC: (Continued on following page) | BzBr-FC has significantly superior IOP-lowering activity |

(Continued on following page)
## TABLE 6 | (Continued) A summary of clinical trials comparing different fixed combination and non-fixed combination agents.

| First author/Year/References | Study design | Evaluation period | Diagnosis | Glaucoma medications | Mean baseline IOP (mmHg) | Post treatment IOP (mmHg) | Adverse effects | Comments |
|---|---|---|---|---|---|---|---|---|
| Sebold et al. (2017) | prospective, multicenter, double-masked, parallel-group clinical trial | 24 h | OAG, OHT | BzBr-FC (30); Timolol (30) | The baseline 24 h IOP: 20.2 ± 0.5 mmHg, Brinzolamide: 17.2 ± 0.8 mmHg, Brimonidine: 19.7 ± 0.5 mmHg, | The mean 24 h IOP reduction: BzBr-FC: 2.0 ± 0.3 mmHg, Timolol: 1.2 ± 0.3 mmHg, The mean diurnal IOP change: BzBr-FC: 2.7 ± 0.4 mmHg, Timolol: 2.1 ± 0.43 mmHg, The mean nocturnal IOP change: BzBr-FC: 0.8 ± 0.3 mmHg, Timolol: ±0.6 ± 0.2 mmHg | – | Both BzBr-FC and timolol significantly lower IOP during the diurnal period. During the nocturnal period, the effect is lessened but remains significant for BzBr-FC, while timolol fails to reduce IOP overnight. |
| Nguyen et al. (2013) | Phase 3, multicenter, double-masked, parallel-group | 3 months | OAG, OHT | BzBr-FC (218); Brinzolamide (229); Brimonidine (232) | 24.1–27.2 mmHg; 27.2–24.2 mmHg; 23.7–27.3 mmHg | The mean IOP reduction: BzBr-FC: 5.4–8.4 mmHg, Brinzolamide: 4.2–5.7 mmHg, Brimonidine: 3.1–6.5 mmHg | Blurred vision, eye pruritus, dysgeusia: BzBr-FC: 4.5%, 2.3%, 4.1%; Brinzolamide: 6.8, 1.3, 10.3%; Brimonidine: 0, 0, 0.4%; Conjunctivitis, dry mouth, eye allergy: BzBr-FC: 1.8, 2.7, 4.5%; Brinzolamide: 0, 0, 0%; Brimonidine: 3.0, 2.1, 0.9%; The rate of discontinued participation: BzBr-FC: 11.3%, Brinzolamide: 2.1%, Brimonidine: 9.4% | BzBr-FC has significantly superior IOP-lowering activity compared with either brinzolamide or brimonidine, while providing a safety profile which is consistent with that of the individual components |
| Sargin Akcay et al. (2013) | randomized, double-blinded, active-controlled, parallel-group trial | 3 months | OAG, OHT | BzT-FC (57); DzT-FC (57) | 24.6–29.9 mmHg | The mean IOP: BzT-FC: 16.26–18.99 mmHg, DzT-FC: 16.35–19.00 mmHg; The mean IOP reductions: BzT-FC: 6.42–9.74 mmHg (26.09–37.46%), DzT-FC: 8.16–12.41 mmHg (31.19–41.44%) | Blurred vision, Ocular irritation, Eye pain, Foreign body sensation: BzT-FC: 33.3, 7.01, 5.2%; DzT-FC: 10.5, 33.3, 29.8, 28.07% | DzT-FC and BzT-FC provided comparable IOP-lowering effect, while greater ocular discomfort was happened in DzT-FC group. BzT-FC treatment may provide a better patient experience and improve therapeutic compliance |
| Hartleben et al. (2017) | multicenter, double-masked, randomized, phase 3 study | 12 weeks | POAG, OHT | BBtFC (93); BrtFC (97) | 24.62 ± 2.48 mmHg; BrtFC: 25.12 ± 2.18 mmHg | The mean IOP reductions: BBtFC: 10.03 mmHg, BrtFC: 9.18 mmHg; The proportion of IOP-13 mmHg: BBtFC: 33.7%, BrtFC: 14.8% | The incidence of treatment-related AEs: BBtFC: 52.7%, BrtFC: 27.8%; The percentage of discontinuations: BBtFC: 5.4%, BrtFC: 4.1%; Conjunctival hyperemia, Eye irritation, Dry eye, Eye pruritus, Somnolence: BBtFC: 23.7, 14.0, 8.6, 6.5, 4.3%; BrtFC: 3.1, 4.1, 1.0, 2.0, 8.2% | BBtFC had superior ocular hypertensive effects (compared with BrtFC). Although, the ocular side effects of BBtFC are more serious than BrtFC, BBtFC offers IOP-lowering benefits that may outweigh the risk |
| Belfort et al. (2020) | randomized, masked, | 12 weeks | POAG, OHT | BBtFC (90); BrtFC (95) | 25.4 mmHg; 24.4 mmHg | The mean IOP: BBtFC: 15.0 mmHg, BrtFC: 16.0 mmHg; The mean changes: BzBr-FC: 0.2 mmHg; Brinzolamide: 0.3 mmHg, Timolol: 0.4 mmHg; The mean diurnal IOP change: BzBr-FC: 0.8 ± 0.3 mmHg, Timolol: ±0.6 ± 0.2 mmHg | The incidence of treatment-related AEs: BBtFC: 72.2%, BrtFC: 68.8%; The mean IOP reductions: BBtFC: 2.7 ± 0.4 mmHg, BrtFC: 2.3 ± 0.4 mmHg; The proportion of IOP-13 mmHg: BBtFC: 33.7%, BrtFC: 14.8% | BBtFC provided clinically and statistically significant IOP-lowering effects compared with either brinzolamide alone or brimonidine alone in patients with open-angle glaucoma or ocular hypertension while providing a safety profile consistent with that of its individual components |
TABLE 6 | (Continued) A summary of clinical trials comparing different fixed combination and non-fixed combination agents.

| First author/Year/References | Study design | Evaluation period | Diagnosis | Glaucoma medications | Mean baseline IOP (mmHg) | Post treatment IOP (mmHg) | Adverse effects | Comments |
|-----------------------------|--------------|-------------------|-----------|----------------------|--------------------------|---------------------------|----------------|----------|
| Fechtner et al. (2011)      | prospective, randomized, multicenter, investigator-masked, parallel-group study | 12 weeks | OAG | BrT-FC + Latanoprost (102); LT-nFC (102) | 23.4–23.7 mmHg; 23.0–23.5 mmHg | The mean IOP: 15.1–17.0 mmHg; 16.9–17.7 mmHg | The incidence of treatment-related AEs: BrT-FC + Latanoprost: 9.8%, LT-nFC: 3.9%; The incidence of ocular AEs: BrT-FC + Latanoprost: 8.8%, LT-nFC: 6.9 | significantly superior IOP-lowering efficacy than did DFC with no unexpected AEs or marked worsening of expected AEs arising from the combination of these 3 medications into 1 ophthalmic solution BrT-FC reduces IOP significantly more effectively than timolol when used as therapy adjunctive to latanoprost. Adjunctive treatment with BrT-FC was also well tolerated. BrT-FC + Travoprost achieves a better mean 24-h IOP control. |
| Konstas et al. (2013a)      | prospective, observer-masked, active controlled, crossover, comparison | 3 months | POAG | BzT-FC + Travoprost (23); BrT-FC + Travoprost (27) | 20.1 mmHg | The mean 24 h IOP: BrT-FC + Tr: 17.2 mmHg, BrT-FC + Tr: 18.0 mmHg. The mean 24 h IOP fluctuation: BzT-FC + Tr: 3.6 mmHg, BrT-FC + Tr: 4.3 mmHg | Hypertrichosis, Systemic hypotension, Dry eye sensation | Burning/stinging; Watering; Superficial punctate keratitis |
| Konstas et al. (2008)       | prospective, observer-masked, placebo controlled, crossover, comparison | 3 months | OAG | DzT-FC + Latanoprost; DzT-FC; LT-FC | 22.1 mmHg | The mean IOP reduction: DzT-FC + Latanoprost: 5.6 mmHg, DzT-FC: 2.2 mmHg, LT-FC: 2.7 mmHg; The mean 24 h IOP fluctuation: DzT-FC + Latanoprost: 3.6 mmHg, DzT-FC: 4.4 mmHg, LT-FC: 4.1 mmHg | — | DzT-FC as an adjunct to latanoprost may further enhance pressure reduction |
| Hatanaka et al. (2010)      | prospective, open-label, randomized, controlled clinical Trial | 4 weeks | OAG | DzT-FC + Latanoprost (49); Latanoprost (49) | 15.24 ± 2.84 mmHg; 15.34 ± 2.96 mmHg | The mean IOP: DzT-FC + Latanoprost: 14.44 ± 3.03 mmHg, Latanoprost: 15.60 ± 3.09 mmHg | — | The combination of PF-DzT-FC and PF-Tafluprost provided statistically greater 24-h efficacy and improved tolerability |
| Konstas et al. (2017)       | prospective, observer-masked, crossover, comparison | 24 h | OAG | PF-DzT-FC + PF-Tafluprost (21); PF-Tafluprost (22) | 22.2 ± 2.9 mmHg | The mean 24 h IOP: PF-DzT-FC + PF-Tafluprost: 17.3 ± 2.7 mmHg, PF-Tafluprost: 21.9 ± 3.2 mmHg; The mean Daytime IOP: PF-DzT-FC + PF-Tafluprost: 17.0 mmHg, PF-Tafluprost: 22.3 mmHg; The mean Nighttime IOP: PF-DzT-FC + PF-Tafluprost: 17.6 mmHg, PF-Tafluprost: 21.5 mmHg | Corneal stain (van Bijsterveld score), Schirmer test (mm); Break-up time (s); PF-DzT-FC + PF-Tafluprost: 1.7, 8.2, 6.1; PF-Tafluprost: 1.3, 9.1, 6.7; Stinging, Hyperemia, Blunting of vision, Itchiness: PF-DzT-FC + PF-Tafluprost: 20.9, 9.3, 4.6, 23.6; PF-Tafluprost: 6.9, 11.6, 6.9, 6.9% | — |
| Topouzis et al. (2021)      | Phase 4, randomized (1:1), double masked, parallel group trial | 6 weeks | OAG | BrBz-FC + PGA (96); PGA (92) | 28.8 mmHg; 28.9 mmHg | The mean diurnal IOP change: BrBz-FC + PGA: −5.59 mmHg, PGA: 2.15 mmHg | BrBz-FC as an adjunct to PGA is a suitable treatment option for patients with open-angle glaucoma or ocular hypertension for whom PGA monotherapy provides insufficient IOP reduction. The safety profile of BrBz-FC + PGA was consistent with the known safety profiles | — |

(Continued on following page)
Anastasopoulos, 2018). EP1-4 receptors are widely distributed in the human cornea, conjunctiva, TM, iris, ciliary body, and retina (Doucette and Walter, 2017; Matsou and Anastasopoulos, 2018). PGE2 receptor agonists increase uveoscleral outflow and induce morphological alterations in the tissues involved in the conventional pathway to decrease IOP by binding to EP1-4 receptors (Matsou and Anastasopoulos, 2018).

Prostaglandin E2 Receptor EP2 Subtype Agonists

Omidenepag Isopropyl (DE-117/G0G0H52U6K/STN-10117, Eybelis®).

Efficacy. Omidenepag isopropyl (OMDI) is a prodrug of omidenepag (Duggan, 2018) through the increase of both TM and uveoscleral outflow (Fuwa et al., 2018). The optimal dose of OMDI is 0.002% as demonstrated in the clinical trials (Aihara et al., 2019; Aihara et al., 2020a). IOP lowering effect of OMDI (0.002%) is not inferior to latanoprost (0.005%) (Aihara et al., 2019). The mean reduction of IOP after 4 weeks is 5.93 and 6.56 mmHg in the patients treated with OMDI (0.002%) and latanoprost (0.005%), respectively (Aihara et al., 2020a). In a phase 3 study, the percentage of the mean diurnal IOP reduction is 13.23% after 4 weeks of OMDI (0.002%) in patients who accepted latanoprost 0.005% with a reduction of IOP ≤15% during 8 weeks (Aihara et al., 2020b).

Safety and AEs. OMDI has better safety than latanoprost (Aihara et al., 2019). The ocular AEs induced by OMDI is mild or moderate, and the most frequently reported are conjunctival hyperemia, photophobia, and eye pain (Aihara et al., 2020a; Inoue et al., 2020a; Aihara et al., 2020b). Conjunctival hyperemia is dose-dependent (Aihara et al., 2019), and most frequently observed in small vessels (51%) in OMDI-treated eyes, and in both large and small vessels (81%) in ripasudil-treated eyes (Terao et al., 2020).

Aganepag Isopropyl (AGN-210961). AGN-210961 has been formulated as a proprietary ophthalmic solution (Impagnatiello et al., 2019). Both AGN-210961 and bimatoprost 0.03% exert a similar IOP lowering effect at day 7 and week 4, as demonstrated by a clinical trial (NIH, 2014a). AGN-210961 do not exert any serious AEs, and the incidence of AEs in AGN-210961 group is also lower than bimatoprost group (NIH, 2014a).

AGN-210669. AGN-210669 is a sustained-release formulation of AGN-210961 (Impagnatiello et al., 2019) used in clinical trials for the treatment of POAG and OHT. But the safety and effectiveness of AGN-210669 is not superior to bimatoprost (NIH, 2013b; a). The combination of AGN-210669 (0.05%) and bimatoprost does not induce a significant change in the IOP lowering effect, and the AEs of the combination therapy also increased (NIH, 2013b; a). Therefore, AGN-210669 may not be a better medicine to control IOP.

Prostaglandin E2 Receptor EP3 Subtype Agonists

Sepetaprost (ONO-9054/DE-126).

Efficacy. The prodrug ONO-9054 is an isopropyl ester derivative of the biologically active free acid ONO-AG-367 in the treatment of glaucoma and OHT (Impagnatiello et al., 2019; Bhattaccharjee et al., 2020). ONO-9054 can rapidly be converted into ONO-AG-367 after ocular instillation and is characterized by dose-dependent systemic pharmacokinetics with rapid clearance (Suto et al., 2015; Harris et al., 2016).

A phase 1 clinical trial in OHT and POAG patients demonstrated that ONO-9054 reduces IOP in a dose-dependent manner and the greatest reduction is 29.6% at 9 h after the dose of ONO-9054 of 30 μg/ml on day 1 (Harris et al., 2016). In healthy volunteers, the mean reduction is 8.29 mmHg (28.2%) at 9 h after a dose of ONO-9054 of 30.0 μg/ml (Suto et al., 2015). The morning (AM) and evening (PM) dosage of 30 μg/ml ONO-9054 have similar sustained reduction in IOP, whereas the incidence of hyperemia and dryness is slightly increased in the patients subjected to the PM dose of ONO-0954 (Berlin et al., 2016). Miller Ellis, et al. observed that ONO-9054 (30 μg/ml) has a better IOP lowering effect than Xalatan once daily (Miller Ellis et al., 2017). The rate of the mean IOP reduction of ≤−25%, ≤−30%, and ≤−35% in the ONO-9054-treated patients is 2.39, 2.37, and 4.85 times higher than the rate in the Xalatan-treated
patients, and 2.4 times more patients achieve an IOP ≤15 mmHg than those treated with Xalatan (Miller Ellis et al., 2017).

**Safety and AEs.** ONO-9054 is well-tolerated and all AEs have a mild or moderate intensity (Miller Ellis et al., 2017). The AEs frequently reported are headache, anterior uveitis, vitreous detachment, conjunctival hyperemia, and blurred vision (Harris et al., 2016; Miller Ellis et al., 2017).

### 3.1.3 Nitric Oxide-donating Prostaglandin F2-Alpha Analog

Nitric oxide (NO)-donating prostaglandin is composed of a prostaglandin F2 analogue moiety and NO-donating moiety, thus providing an IOP-lowering effect by two independent mechanisms (Impagnatiello et al., 2019). NO is an endogenous gas working as a signaling molecule inducing TM and Schlemm’s canal cell relaxation, decreasing cell volume, enlarging cell gap, and decreasing the outflow resistance through the activation of the soluble guanylyl cyclase/cyclic guanosine monophosphate (sGC-cGMP) signaling pathway (Krauss et al., 2011; Kaufman, 2017; Cavet and DeCory, 2018; Mao et al., 2020). In addition, it decreases AH production by inhibiting the Na⁺, K⁺-ATPase pump eventually lowering IOP (Wareham et al., 2018). NO also regulates the eye blood flow and protects the optic nerve by the sGC-cGMP signaling pathway (Wareham et al., 2018; Mao et al., 2020).

**Latanoprostene Bunod (Vyzulta®)**

**Efficacy.** LBN is the first NO-donating prostaglandin F2-alpha analog on the market (Addis and Miller-Ellis, 2018; Hoy, 2018a; Mehran et al., 2020). LBN administered every evening (QD) exerted a significantly greater effect and it is safer than timolol 0.5% (BID) (Kawase et al., 2016; Liu et al., 2016; Weinreb et al., 2016; Weinreb et al., 2018). The mean IOP is significantly lower in the LBN-treated patients (17.8–18.9 mmHg) than in those treated with timolol 0.5% (19.0–19.7 mmHg) at all time points (week 2, week 6, and month 3). A total of 22.9% patients treated with LBN achieved a mean IOP ≤18 mmHg, which is significantly more than that in those treated with timolol (11.3%) (Weinreb et al., 2016).

**Safety and AEs.** LBN is well-tolerated with no serious AEs and system AEs. Conjunctival hyperemia, eye irritation, and eye pain are the most reported ocular AEs (Medeiros et al., 2016). Blood pressure or heart rate does not change in correlation with LBN treatment (Kawase et al., 2016; Liu et al., 2016).

**NCX 470**

**Efficacy.** NCX-470 is a novel NO-donating bimatoprost with potentially greater IOP-lowering effect than bimatoprost monotherapy (Impagnatiello et al., 2015). A phase 2 clinical trial demonstrated that NCX-470 with well-tolerated was non-inferiority to latanoprost monotherapy (NIH, 2019a). The mean IOP reduction were 7.6–9.8 mmHg and 6.3–8.8 mmHg at day 28 in NCX-470 group and latanoprost group (NIH, 2019a).

**Safety and AEs.** Little evidence was found of treatment-related systemic effects or drug-related serious AEs associated to NCX-470. Conjunctival hyperemia was the most frequent AE in 16.8% of patients treated with NCX-470 (0.065%) versus 6.5% of patients treated with latanoprost (NIH, 2019a).

### 3.2 Rho-Kinase Inhibitors

The rho-kinases are serine/threonine kinase isoforms and effectors (Schelheim and Robin, 2019). Topical rho-kinase inhibitors inhibit rho-kinase isoforms in TM, thus directly increasing AH outflow in the TM pathway and consequently reducing IOP in a significant manner (Berrino and Supuran, 2019; Moura-Coelho et al., 2019). Rho-kinase inhibitors also exert a neuroprotective effect that in turn can exert a greater positive impact on the ocular blood flow, and even an antibifrocetic effect that may be helpful if conventional glaucoma surgery is needed (Tanna and Johnson, 2018) (Table 2).

#### 3.2.1 Launched Rho-Kinase Inhibitors

**Ripasudil (Glanatec®)**

**Efficacy.** Ripasudil is the first rho-kinase inhibitor approved for the treatment of glaucoma (Berrino and Supuran, 2019). It promotes AH outflow by changing the TM cytoskeleton to reduce the outflow resistance and increasing the endothelial permeability of the Schlemm’s canal (Schelheim and Robin, 2019). Multiple clinical trials reported that ripasudil provides a great IOP lowering effect and exerts an additional reduction of IOP when used an add-on medication to PGAs and β-blockers (BBs) (Tanihara et al., 2013; Tanihara et al., 2016; Inoue and Tanihara, 2017). A phase 2 clinical study demonstrated that IOP-lowering effect of ripasudil is dose-dependent. When patients are treated with 0.1, 0.2, and 0.4% ripasudil for 8 weeks, the mean IOP reductions are 3.4 mmHg, 3.2 mmHg, and 3.5 mmHg, respectively (Tanihara et al., 2013).

**Safety and AEs.** Conjunctival hyperemia is the most frequent AE caused by ripasudil (Tanihara et al., 2013; Tanihara et al., 2016; Sakamoto et al., 2019) due to the relaxation of the smooth muscle in the blood vessels because of the inhibition of rho-kinase. However, this AE is mild, transient, and can resolve spontaneously in glaucoma patients (Sakamoto et al., 2019; Kusuhara and Nakamura, 2020). The other frequently observed AEs are blepharitis and allergic conjunctivitis (Tanihara et al., 2016).

**Netarsudil (Rhopressa®)**

**Efficacy.** Netarsudil reduces the high IOP by inhibiting rho-kinase and norepinephrine transporter (Hoy, 2018b; Mehran et al., 2020). In this way, it increases TM outflow and reduces the episcleral venous pressure (Kazemi et al., 2018). Netarsudil 0.02% is well-tolerated and has a similar IOP lowering effect to timolol 0.5% twice daily (Kazemi et al., 2018; Serle et al., 2018; Khouri et al., 2019; Singh et al., 2020). Netarsudil once daily (PM) and twice daily have similar IOP lowering effect (Khouri et al., 2019). The mean IOP reduction at 3 months after netarsudil once daily and twice daily, as well as timolol twice daily is 16–21%, 22–24%, and 18–23% respectively (Serle et al., 2018).
Safety and AEs. Netarsudil causes non-serious AEs, generally mild in intensity (Kazemi et al., 2018; Serle et al., 2018; Kahook et al., 2019). The most frequent ocular AE is conjunctival hyperemia (Singh et al., 2020), followed by corneal deposits and conjunctival hemorrhage (Serle et al., 2018; Kahook et al., 2019). Other AEs include instillation site pain, blurred vision, increased lacrimation, reduction of visual acuity, eye pruritus, and erythema of the eyelid (Serle et al., 2018; Kahook et al., 2019).

3.2.2. Clinical Rho-Kinase Inhibitors

RKKI-983/SNJ-1656/Y-39983

SNJ-1656, also called Y-39983 or RKKI-983, promotes the regeneration of the axon in damaged retinal ganglion cells (Yang et al., 2013). However, the IOP lowering effect is not very remarkable. In a phase I clinical trial, the mean IOP reductions are 2.2, 3.8, 4.3, and 4.0 mmHg before the instillation of the eyedrops in the morning and 1.5, 5.0, 4.4 and 4.5 mmHg at 2 h after the instillation in the morning in placebo and SNJ-1656 (0.03, 0.05 or 0.1%) group (Inoue et al., 2015). AEs are mild to moderate, and conjunctival hyperemia is the most frequently reported (Inoue et al., 2015).

AMA-0076/PHP-201

AMA0076, also called PHP-201, contains carboxylic ester moieties that allow the inactivation by esterase, resulting in an increased therapeutic window (Van de Velde et al., 2014). AMA0076 with a similar IOP-lowering efficacy as Y-39983 and latanoprost was demonstrated in the white rabbit experiment, and AMA0076 was more potent in preventing the long-term IOP-lowering effect (Chen et al., 2020). However, no result of AMA-0076 on clinical trials was published.

Y-27632

Y-27632 is used in the treatment of OHT since it modulates the cytoskeletal alterations in TM cells to increase the conventional outflow, and relax the ciliary muscle contraction (Chen et al., 2020; Luo et al., 2021). At present, there is no related clinical study, but glaucomatous transgenic mice experiment demonstrated that Y-27632 can significantly decreased IOP and increased outflow facility, which greatly influenced the long-term IOP-lowering effect (Chen et al., 2020).

3.3 β-adrenergic Blocking Agents

BBs actively block the β-adrenergic receptors and their pharmacological properties depend on their various effects on the adrenergic signaling pathway (Bejan-Angoulvant and Angoulvant, 2020). The ocular AEs include conjunctival hyperemia, ocular surface discomfort, reduction in tear flow, and worsening of the dryness in the eye, while the systemic AEs include bradycardia, heart block and arrhythmia, bronchospasm, and worsening of underlying asthma or chronic obstructive pulmonary disease (Dikopf et al., 2017). These AEs are caused by the direct systemic absorption of BBs after ocular administration through the nasolacrimal system or the conjunctiva, without being subjected to first pass metabolism (Morales et al., 2016; Shukla et al., 2020). Although topical BBs is not associated with excess cardiovascular mortality as revealed in a meta-analysis with large population-based studies (Pinnock et al., 2016), ophthalmic BBs are not recommended in patients with asthma, chronic obstructive pulmonary disease, bradycardia, heart block, or uncontrolled heart failure (Marshall et al., 2018) (Table 3).

3.3.1 Nonselective β-adrenergic Blocking Agents

Nonselective BBs reduce IOP by blocking β-adrenoceptor in the ciliary body and consequently decreasing AH production (Nocentini and Supuran, 2019). Timolol maleate (Timoptol®) is the first nonselective BB for the topical treatment of glaucoma and OHT (Sah and Suresh, 2017) and it reduces IOP by 27–35% (Nocentini and Supuran, 2019). Carteolol hydrochloride (Mikelan®) protects against light-induced oxidative stress in retina (Matsu et al., 2019).

3.3.2 Selective β-1 Adrenergic Blocking Agents

Betaxolol hydrochloride (Betoptic®) is a selective β1-blocker for the topical treatment of glaucoma, exerting an IOP reduction of 18–26% less than timolol (Dikopf et al., 2017).

3.3.3 Selective β-2 Adrenergic Blocking Agents

Bamosiran (SYL040012)

Efficacy. SYL040012 targets the human β2-adrenergic receptor to inhibit its expression and consequently reduces the production of AH (Martinez et al., 2014; Jiang et al., 2021). It is also the first compound based on RNA interference (Moreno-Montanes et al., 2014). A phase I clinical trial demonstrated that no significant difference in IOP was found between the patients treated with 600 µg/eye once daily and those treated with 900 µg/eye twice daily (Moreno-Montanes et al., 2014). Patients in a phase 2 study were randomly divided to receive 80 µg (0.2%), 300 µg (0.75%), 900 µg (2.25%) SYL040012 or placebo once daily, and the results showed that 0.75% SYL040012 exerted a statistically significant reduction in IOP at day 14 (NIH, 2014c). More clinical studies are needed to explore the optimal dosing of SYL040012.

Safety and AEs. The AEs occur when SYL040012 is administered twice daily and include headache, conjunctival hyperemia, muscle spasm, unilateral stinging, bilateral itching, and difficulty in focusing. The diastolic blood pressure is significantly reduced only in patients treated with SYL040012 at 600 µg/eye twice daily (Moreno-Montanes et al., 2014).

3.4 α-2 Adrenergic Agonists

α-adrenergic is divided into α1 and α2, which are the ones involved in the regulation of IOP. Ocular α2-adrenoceptor induces conjunctival vasoconstriction, increases interpalpebral fissure, mydriasis, and decreases corneal oxygen tension (Cimolai, 2020). Brimonidine tartrate reduces AH production and increases the flow in TM and uveoscleral pathways (Nocentini and Supuran, 2019; Cimolai, 2020). Brimonidine tartrate (Alphagan®) is often administered as second line
therapy or combined with other topical medications for the topical treatment of glaucoma and OHT (Hopf et al., 2020) resulting in an IOP reduction of 20–27% (Nocentini and Supuran, 2019; Cimolai, 2020). Brimonidine also offers a neuroprotective effect (Zhou et al., 2019; Conti et al., 2021). The significant AEs include blepharitis, blepharoconjunctivitis, conjunctivitis, conjunctival follicles, mild hyperemia, staining of the cornea, blurred vision, and foreign body sensation (Dikopf et al., 2017; Nocentini and Supuran, 2019) (Table 4).

3.5 Carbonic Anhydrase Inhibitors

Human carbonic anhydrase (hCA) is present in all living organism and it catalyzes carbon dioxide hydration that is regulating many physiological processes (Supuran et al., 2019; Supuran, 2020). hCA inhibitors exert IOP lowering effect by decreasing bicarbonate and AH secretion through the inhibition of hCA II, IV, and XII isoforms. (Supuran et al., 2019; Ghorai et al., 2020). The first generation CAs inhibitors are sulfonamide hCA-II inhibitors including acetazolamide, methazolamide, and dichlorphenamide, which decrease IOP by 25–30% (Scorzafava and Supuran, 2014; Ghorai et al., 2020). They have been used as systemic antiglaucoma drugs for more than 50 years, but certain undesirable AEs are reported due to the inhibition of the enzymes present in the tissues than the ones in the eye (Carradori et al., 2015). The second generation of CAs inhibitors topically administered are sulfonamides, such as dorzolamide hydrochloride (Trusopt ®) and brinzolamide of CAs inhibitors topically administered are sulfonamides, such as dorzolamide hydrochloride (Trusopt ®) and brinzolamide (Azopt®), whose IOP lowering effect is comparable with the one of BBs, but less effective than PGAs (Eichhorn, 2013). Trusopt® and Azopt® are characterized by a better tolerance and less AEs compared to the first generation inhibitors, and the common reported AEs include stinging, burning or reddening of the eye, blurred vision, pruritus and bitter taste (Scorzafava and Supuran, 2014) (Table 4).

3.6 Adenosine Receptor Agonists

Adenosine is an essential component of the energy production and utilization systems of the body by providing the energetics necessary for the muscle movements, heartbeat, nerve signals, and chemical reactions (Jamwal et al., 2019). It exerts its functions by activating four adenosine receptor (AR) subtypes (A1, A2A, A2B, and A3) (Ciancetta and Jacobson, 2017). Adenosine is neuroprotective against excitotoxicity and metabolic dysfunctions that may be present in neurological and ocular diseases (Jamwal et al., 2019) (Table 4).

3.6.1 Trabodenoson (INO-8875)

Efficacy

Trabodenoson is an adenosine mimetic that selectively acts on the A1 receptor subtype (Qiu, 2021). Trabodenoson can involve in matrix metalloproteinase signaling pathway associated with glaucoma (Qiu, 2021), consequently increasing TM outflow and exerting IOP lowering effect (Li et al., 2018). Trabodenoson exerts a dose-dependent and time-dependent IOP lowering effect (Myers et al., 2016). When patients receive of trabodenoson topical administration at the dose of 50, 100, 200, or 500 μg twice daily exerts a mean IOP reduction at day 14 to 1, 1.67, 2.5, and 3.2 mmHg, respectively, and a reduction to 4.1 mmHg with the dose of 500 μg at day 28 (Myers et al., 2016).

Safety and AEs

Trabodenoson has a good safety profile (Latties et al., 2016; Myers et al., 2016). The common systematic AEs such as headache, eye pain, back pain, dermatitis, and excoriation, were more frequently observed in the placebo-treated patients than in the trabodenoson-treated patients (Latties et al., 2016). Ocular AEs are uncommon and not serious, present for not longer than 24 h, and they are self-limited, and are usually mild in intensity (Latties et al., 2016).

4 TOPICAL FIXED COMBINATION OF TWO AGENTS

4.1 Fixed Combination of Prostaglandin F2a Analogs and β-blockers

4.1.1 Fixed Combination Latanoprost and Timolol (Xalacom®)

Efficacy

LT-FC is currently one of the most widely used topical anti-glaucoma fixed-combination eye drops, which is usually chosen to cure patients with POAG and OHT who are insufficiently responsive to BBs, PGs, or other IOP lowering agents (Konstas et al., 2013c). LT-FC exerts a superior IOP lowering effect than the monotherapy using latanoprost or timolol. Mean IOP at 12 weeks is reduced to 10.2 mmHg in the LT-FC-treated patients, 8.9 mmHg in the latanoprost-treated patients and 7.2 mmHg in the timolol-treated patients and 73.5, 57.5, and 32.8% patients achieve a diurnal IOP reduction over 30% (Higginbotham et al., 2010). Zhao, et al. reported the IOP lowering effect of LT-FC versus non-fixed combination of latanoprost and timolol (LT-nFC), and their results revealed that LT-FC is noninferiority to LT-nFC regarding the mean diurnal IOP reduction after 8 weeks (8.6 versus 8.9 mmHg) (Zhao et al., 2011). Importantly, LT-FC shows a better compliance than LT-nFC (Zhao et al., 2011).

Safety and AEs

Various studies show similar AEs in patients treated with LT-FC, LT-nFC, latanoprost, and timolol monotherapies, and the most commonly reported one is conjunctival hyperemia (Higginbotham et al., 2010).

4.1.2 Fixed Combination Bimatoprost and Timolol (Ganfort®)

Efficacy

Bit-FC has present in the market of more than 30 countries and regions worldwide OHT used for the reduction of IOP in patients with POAG (Fang et al., 2015). Bit-FC significantly decreases IOP in a greater extent than PGA, or timolol monotherapy (Lewis et al., 2010; Lequeu et al., 2013). Bit-FC also has better 24 h-IOP controlling effect than latanoprost monotherapy (Konstas et al., 2013b). The rates of the mean diurnal IOP reduction over 20% are 68.1, 58.1, and 38.0% in Bit-FC, bimatoprost, and timolol-treated patients, respectively, and the rates of IOP less than 18 mmHg are 23.3, 18.1, and 8.0%, respectively (Lewis et al., 2010). The mean 24-h IOP reduction
was 12.2 mmHg (39.2%) in BiT-FC group, which was better than that in latanoprost group (9.9 mmHg, 31.9%) (Konstas et al., 2013b).

**Safety and AEs**

No addition AEs and serious AEs are reported in BiT-FC treatment group. Although, the incidence of AEs is more in the bimatroprost-treated patients (60.0%) than in the BiT-FC- (48.0%) and timolol-treated patients (31.6%), it is acceptable. Conjunctival hyperemia is the most frequently observed AE, with an incidence of 43.4% by bimatropost, followed by 25.7% of BiT-FC and 8.7% of timolol (Fang et al., 2015).

### 4.1.3 Fixed Combination of Travoprost and Timolol (DuoTrav®)

**Efficacy**

TrT-FC is preserved with benzalkonium chloride (BKC) and it is already introduced into the global market (Hoy et al., 2006; Konstas et al., 2012). Preservative-free (PF)-TrT-FC is one of the most recent PF agents that become available in Europe, which reduce the toxicity and improve the long-term health of the ocular surface in a better manner than TrT-FC (Denis, 2011; Konstas et al., 2012). A total of 162 patients in a prospective multicenter open-label study were treated with PGA monotherapy (travoprost, latanoprost, tafluprost, or bimatropost) for over 3 months, then they switched to TrT-FC, and the observed reduction in IOP was 10.3 ± 12.7% (1.7 ± 3.1 mmHg), 9.4 ± 14.3% (1.6 ± 3.3 mmHg), and 10.1 ± 13.0% (1.7 ± 3.2 mmHg) after 4, 8, and 12 weeks, respectively (Nakano et al., 2015).

**Safety and AEs**

The most frequently observed AEs after TrT-FC treatment are ocular hyperemia, ocular discomfort, pruritus, and dryness (Hoy et al., 2006). Although, timolol has systemic side effects, a significant change from the baseline value of the mean systolic blood pressure is observed when patients switch to TrT-FC from PGA monotherapy (Nakano et al., 2015).

### 4.1.4 Fixed Combination of Tafluprost and Timolol (Tapcom®)

**Efficacy**

PF-TIT-FC was used for the reduction of IOP in adults with OAG or OHT who require a combination therapy because they are insufficiently responsive to topical monotherapy with BBs or PGs (Hoy, 2015). PF-TIT-FC has a superior IOP lowering effect compared with agents used as monotherapy (Pfeiffer et al., 2014; Kaarniranta et al., 2016; Konstas et al., 2018), which is more suitable for evening administration (Konstas et al., 2018). In a phase 1 study, the result of the mean IOP was 10.3 mmHg for PF-TIT-FC, 10.9 mmHg for PF-tafluprost, and 11.1 mmHg for PF-timolol after 8 days in healthy volunteers (Kaarniranta et al., 2016). In another clinical trial, 189 patients treated with timolol who switched to PF-TIT-FC (n = 95) or PF-timolol (n = 94), showed a reduction of IOP to 7.1–9.0 mmHg in the PF-TIT-FC-treated patients and 6.5–8.1 mmHg in the timolol-treated patients and 375 patients treated with PGA who switched to PF-TIT-FC (n = 188) or PF-tafluprost (n = 187) for 3 months showed a reduction of IOP to 8.2–9.0 mmHg in the PF-TIT-FC-treated patients and 6.8–7.4 mmHg in the PF-tafluprost-treated patients (Pfeiffer et al., 2014).

**Safety and AEs**

The rate of AEs is more in the PF-TIT-FC-treated patients than in those treated with the single agent (Pfeiffer et al., 2014). Patients treated with PF-timolol show the lowest incidence (15.2%) of AEs in contrast to patients treated with PF-tafluprost (36.4%) and PF-TIT-FC (48.5%). The commonly reported ocular AEs related to the treatment with PF-TIT-FC include eye pain, eye pruritus, ocular hyperemia, and photophobia (Kaarniranta et al., 2016), while hyperemia is less common in patients treated with PF-TIT-FC than in those treated with PF-latanoprost (7.1% vs 21.4%) (Konstas et al., 2018).

### 4.1.5 Fixed Combination of Latanoprost and Carteolol (Mikeluna®)

**Efficacy**

LC-FC has the same IOP lowering effect as the non-fixed combination of carteolol and latanoprost (LC-nFC) and LT-FC, and exerts a greater effect than carteolol and latanoprost monotherapy (Yamamoto et al., 2016; Inoue et al., 2018; Inoue et al., 2020b). In the study 1 of a two phase 3 clinical trial, 220 patients were treated with LC-FC (n = 113) or latanoprost (n = 116) for 8 weeks, while in the study 2, 175 patients were treated with LC-FC (n = 76), carteolol (n = 76), or LC-nFC (n = 37) for 8 weeks. The adjusted mean IOP reduction in the study 1 was 2.9 and 1.6 mmHg in the LC-FC and latanoprost-treated patients, in the study two was 3.5, 3.5, and 1.6 mmHg in LC-FC, LC-nFC, and carteolol-treated patients (Yamamoto et al., 2016). When patients with POAG or OHT were treated with LC-nFC and then switched to LC-FC, they showed an IOP of 15.0 ± 2.6, 15.1 ± 2.4, and 15.0 ± 2.4 mmHg at baseline, month 1 and 3, respectively (Inoue et al., 2018). When patients with POAG, NTG, or OHT were treated with LT-FC and then switched to LC-FC, they showed a not significantly changed mean IOP after 1 month (15.9 ± 3.1 mmHg) and 3 months (16.3 ± 3.8 mmHg) compared to the baseline IOP with LT-FC (16.1 ± 3.1 mmHg) (Inoue et al., 2020b).

**Safety and AEs**

The AEs related to LC-FC observed in clinical trials are mild (Yamamoto et al., 2016), and common ocular AEs include hyperemia, irritation, itching, pain, and blurred vision (Inoue et al., 2018). The incidence of ocular AEs decreases when the therapy switches from LC-nFC to LC-FC (Inoue et al., 2018), so LC-FC may provide better tolerance. The pulse rate and blood pressure do not significantly change in patients treated with LC-FC (Yamamoto et al., 2016; Inoue et al., 2018).

### 4.1.6 Comparison of the Fixed Combination of Prostaglandin F2a Analogs and β-blockers

When comparing the efficacy of TrT-FC with that of LT-FC, the former showed a greater IOP lowering effect (Shoji et al., 2013; Konstas et al., 2014). Mean 24-h IOP reduction was 2.6 mmHg in patients treated with PF-TrT-FC and 2.2 mmHg in those treated with LT-FC (Konstas et al., 2014). Mean reduction in IOP from the baseline (14.8 ± 3.3 mmHg) at 12 weeks is significantly greater in patients treated with TrT-FC (2.4 ± 2.3 mmHg) than in those treated with LT-FC (1.1 ± 2.3 mmHg) (Shoji et al., 2013). No significant difference in ocular or systemic AEs is observed between
TrT-FC- and LT-FC-treated patients, but stinging is significantly more in patients treated with LT-FC (19%) than in those treated with latanoprost (4.8%) (Konstas et al., 2014). A comparative study between BiT-FC and LT-FC discovered a significant reduction in IOP from the baseline without any change of the anterior ocular parameters. The biggest difference in IOP between treated and untreated eyes was 1.67 mmHg (13.6%) at 8 h after the instillation of BiT-FC and 1.93 mmHg (17.8%) at 10 h after the instillation of LT-FC. Conjunctival hyperemia is the most frequent AE in BiT-FC- and LT-FC-treated patients (33.3% versus 25.0%) (Shim et al., 2014). A comparative study showed that patients treated with BiT-FC have a lower IOP than those treated with TrT-FC and the mean IOP reduction is 11.17 and 7.89 mmHg after 6 months, respectively (Macky, 2014). However, in another clinical trial in which patients whose IOP were uncontrolled on BiT-FC accepted TrT-FC showed a decrease of the mean IOP by additional 16.5% at week 8 and 69.2% patients reached the target IOP (≤18 mmHg) (Scherzer et al., 2011). The common AEs are similar in BiT-FC- and TrT-FC-treated patients and include ocular hyperemia, ocular burning, blurred vision, foreign body sensation, and allergic reaction, while stinging/burning is less severe in patients treated with TrT-FC (Scherzer et al., 2011). PF-TT-FC is as effective as LT-FC in terms of IOP-reducing effect, and induces fewer AEs such as eye irritation and eye pain, which were significantly reduced in patients using PF-TT-FC (Suzuki et al., 2018). Patients in a phase IV study who switched from BiT-FC to PF-TT-FC for 12 weeks showed an IOP after the treatment with PF-TT-FC that was clinically insignificant and statistically non-inferior compared with BiT-FC (0.34 mmHg difference). However, the related ocular AEs including lacrimation, eye pruritus, and pruritus increase (Bourne et al., 2019). In a prospective, observer-masked, randomized study including 54 patients who received BiT-FC, LT-FC, or TrT-FC, a statistically significant reduction in diurnal/nocturnal IOP was observed with all medications, such as 4.6 ± 2.3 mmHg/3.2 ± 2.8 mmHg, 5.8 ± 2.4 mmHg/2.9 ± 1.9 mmHg, and 4.3 ± 1.7 mmHg/3.0 ± 1.6 mmHg, respectively, but no significant difference was observed among the three groups (Guven Yilmaz et al., 2018).

Overall, fixed combination and non-fixed combination of PGAs and β-blockers result in a similar IOP lowering effect, and both are superior to monotherapy, but fixed-combination medicines can significantly improve patient compliance and tolerance. Comparing to eye drops containing preservatives, preserver free medicines can better decrease the incidence of ocular side effects and increase ocular comfortable. So, it is necessary to modify the eye drops to be preservative-free to improve patient compliance and tolerance.

4.2. Fixed Combination of Prostaglandin F2a Analogs and Rho-Kinase Inhibitors

4.2.1. Fixed Combination of Latanoprost and Netarsudil (Rocklalan®)

Efficacy
NL-FC is a glaucoma eye drop marketed as last and is recently approved by FDA for the treatment of OAG or OHT (Asrani et al., 2020). Multiple comparative studies observed that NL-FC had a superior IOP-lowering effect than netarsudil and latanoprost monotherapy (Asrani et al., 2019; Asrani et al., 2020). The percentage of IOP reduction observed in a phase 3 trial was 30.9–36.7% in patients treated with NL-FC compared to the 21.8–24.9% and 23.3–28.8% in patients treated with latanoprost or netarsudil monotherapy at month 3 (Asrani et al., 2019). Another phase 3 trial showed a mean diurnal IOP reduction to 7.8, 5.2, and 6.2 mmHg, respectively. NL-FC (32.3%) achieved a mean diurnal IOP ≤14 mmHg was 3 times higher than that observed after netarsudil (10.8%) and latanoprost (11.8%) monotherapy (Asrani et al., 2020).

Safety and AEs
NL-FC has a safety profile consistent with that of its individual components (Asrani et al., 2019). Conjunctival hyperemia is the most commonly reported in NL-FC group and netarsudil group (Asrani et al., 2020), which may be blood vessel smooth muscle relaxation and blood vessel dilation due to rho-kinase of calcium sensitization (Mehran et al., 2020).

4.3 Fixed Combination of Prostaglandin F2a Analogs and α-2 Agonists

4.3.1 Fixed Combination of Bimatoprost and Brimonidine

Efficacy
BiBr-FC has been evaluated in a clinical trial for the treatment of glaucoma and OHT as an ophthalmic solution in 2013. IOP lowering effect of BiBr-FC was similar to the one of bimatoprost (0.01%) monotherapy and superior to the one of brimonidine (0.2%) monotherapy (NIH, 2015b).

Safety and AEs
The incidence of AEs is more in patients treated with BiBr-FC (71.05%) than in those treated with bimatoprost (69.44%) and brimonidine tartrate (52.63%) (NIH, 2015b), and common eye disorders include conjunctival hyperemia, eye pruritus, eye discharge, blepharospasm, ocular burning, punctate keratitis, eye pain, foreign body sensation, eye irritation, and blurred vision (Netland et al., 2003; NIH, 2015b). Conjunctival hyperemia and eye pruritus show significantly higher rates in BiBr-FC- and bimatoprost-treated patients than in those treated with brimonidine, while the other AEs are similar in the 3 groups (NIH, 2015b). The similar IOP lowering effect and higher AEs may limit the development of BiBr-FC.

4.4 Fixed Combination of Prostaglandin F2a Analogs and Carbonic Anhydrase Inhibitors

4.4.1 Fixed Combination of Travoprost and Brinzolamide

Efficacy
TrBz-FC was used in phase III clinical studies for the treatment of OHT and OAG since 2014. However, both TrBz-FC and TrBz-nFC show no better IOP lowering effect than its marketed components (Travatan® solution and Azopt® suspension) at
8AM, 10AM, 12PM, 4PM, and 8PM after 6-weeks treatment (NIH, 2015a).

Safety and AEs
TrBz-FC is well-tolerated with no serious AEs and the reported AEs include ocular hyperemia, conjunctival hyperemia, eye irritation, eye pain, and dysgeusia (NIH, 2015a).

4.4.2 Fixed Combination of Latanoprost and Dorzolamide
The fixed combination of latanoprost 0.005% and dorzolamide 2% was used in phase II clinical studies at Alleanza Pharmaceuticals for the treatment of glaucoma in 2013 (NIH, 2014b). The fixed combination of latanoprost (0.0025%) and dorzolamide (2%) will be completed in 2022 (NIH, 2020).

4.5 Fixed Combination of β-blocking and α-2 Adrenergic Agonists
4.5.1 Fixed Combination of Brimonidine and Timolol (Combigan®, Aibeta®)
Efficacy
A fixed combination of brimonidine tartrate 0.2% and timolol 0.5% (Combigan®) was first launched by Canada in 2003. Another fixed combination of the ophthalmic solution composed of 0.1% brimonidine tartrate and 0.5% timolol (Aibeta®) was recently approved in Japan (Suzuki et al., 2020). Many clinical studies showed that BrT-FC had superior IOP lowering effect as well as effects in keeping it under control than their constituent agents (Spaeth et al., 2011; Kim et al., 2016), and it was noninferiority to latanoprost in reducing IOP (Katz et al., 2012). Katz, et al. found that 60.3% of patients treated with BrT-FC achieved diurnal IOP <18 mmHg compared to the 52.0% of patients treated with latanoprost after 12 weeks (Katz et al., 2012).

Safety and AEs
Tolerability and side effects were similar with the contained parts without additional side effects. The most common local AEs of BrT-FC include eye irritation, dry eye, allergic reactions, lid erythema, lid edema, conjunctival follicles, corneal staining/erosion, and lens opacity (Katz et al., 2012; Kim et al., 2016). Systemic AEs in patients treated with BrT-FC included asthma (Kim et al., 2016).

4.6 Fixed Combination of β-blocking and Carbonic Anhydrase Inhibitors
4.6.1 Fixed Combination of Timolol and Brinzolamide (Azarga®)
Efficacy
BzT-FC was launched in several European countries in 2009. It has the lowest daily cost and best effectiveness in China compared to other treatments (Xu et al., 2020). A prospective study demonstrated that bimatoprost and BzT-FC exert similar IOP lowering effects in patients with POAG at 8 weeks (Akyol et al., 2017). Importantly, BzT-FC maybe an appropriate choice for patients after uneventful phacoemulsification cataract surgery using Viscoat and Provisc, because BzT-FC can significant prevents IOP increase during the first 24 h after surgery (Georgakopoulos et al., 2013). In a clinical trial, when patients are treated with BzT-FC immediately after surgery or do not receive any ocular hypotensive medication, IOP changes from a preoperative value of +6.7 ± 2.98, +5.3 ± 3.26, and +1.4 ± 2.46 mmHg at 6, 12, and 24 h, to a postoperative value of −0.3 ± 2.95, +0.23 ± 3.49, and −1.76 ± 2.83 mmHg (Georgakopoulos et al., 2013).

Safety and AEs
BzT-FC is well tolerated (Rossi et al., 2011), although pulse rate and systolic blood pressure significantly change (Dixit et al., 2020). The frequently observed AEs are blurred vision, eye irritation, eye pain, and foreign body sensation (Sezgin Akcay et al., 2013; Alezzandrini et al., 2014; Aihara et al., 2017).

4.6.2 Fixed Combination of Timolol and Dorzolamide (Cosopt®)
Efficacy
DzT-FC (fixed combination of Timolol 0.5% and Dorzolamide 2%) was the first IOP-lowering fixed combination approved by the US Food and Drug Administration (FDA) in the treatment of POAG and NTG (Konstas et al., 2021). PF-DzT-FC1 (preservative-free fixed combination of Timolol 0.5% and Dorzolamide 2%) and PF-DzT-FC2 (preservative-free fixed combination of Timolol 0.5% and Dorzolamide 1%) have also been launched in the market in recent year. In an open-label 2-center study, patients with NTG received DzT-FC for 12 weeks, and IOP was reduced by 21.7% at the peak drug effect and by 23.9% at 8 h after drug administration (Kim et al., 2014). DzT-FC has the same efficacy as latanoprost monotherapy in newly diagnosed NTG patients, and the difference of IOP reduction was 0.39 mmHg (Lee et al., 2016b). Visual-related quality of life and the Glaucoma Symptom Scale were significantly improved at week 8 when patients switched from DzT-FC to PF-DzT-FC1 (Abegao Pinto et al., 2014), and PF-DzT-FC1 showed a mean IOP reduction of 6.3% more than DzT-FC after 12 weeks (Reni et al., 2010). Therefore, preservative-free DzT-FC may be a better choice than preservative DzT-FC.

Safety and AEs
DzT-FC does not exert systemic AEs and the most frequent ocular AEs are eye irritation and ocular hyperemia (Kim et al., 2014; Lee et al., 2016b; a). PF-DzT-FC1 improves local tolerability compared to DzT-FC (Reni et al., 2010; Shedden et al., 2010).

4.6.3 Comparison of the Fixed Combination of β-blocking and Carbonic Anhydrase Inhibitors
Several clinical studies demonstrated that BzT-FC exerts a better IOP-lowering effect (Rossi et al., 2011; Sezgin Akcay et al., 2013). IOP reduction was 6.42–9.74 mmHg (26.09–37.46%) and 8.16–12.41 mmHg (31.19–41.44%), respectively (Sezgin Akcay et al., 2013). But, IOP change from the baseline at 9 AM/11 AM pooled after 8 weeks was similar between BzT-FC (3.3/3.3 mmHg) and DzT-FC (2.9/3.4 mmHg) group (Aihara et al., 2017).
The most common ocular AEs include blurred vision, eye irritation, eye pain, and foreign body sensation (Sezgin Akçay et al., 2013; Aihara et al., 2017). Patients treated with DzT-FC have a significantly higher incidence of ocular irritation (33.3% versus 7.01%), ocular pain (29.8% versus 3.5%), and foreign body sensation (28.07% versus 5.2%) than those treated with BzT-FC, whereas blurred vision was reported more in patients treated with BzT-FC than in those treated with DzT-FC (14% versus 10.5%) (Sezgin Akçay et al., 2013; Aihara et al., 2017).

Generally, both fixed-combination medications represent highly effective without clear superiority of one agent over another; however, patients show more ocular comfortable in BzT-FC group. Comparing to DzT-FC, PF-DzT-FC significantly improved effectiveness and safety, which will be equal to or better than BzT-FC.

4.7 Fixed Combination of α-2 Adrenergic Agonists and Carbonic Anhydrase Inhibitors

4.7.1 Fixed Combination of Brinzolamide and Brimonidine (Simbrinza®)

Efficacy
BzBr-FC was approved in United States and EU for the reduction of high IOP in patients with OAG and OHT, and it is the fixed-combination ophthalmic suspension to treat glaucoma available without timolol (Greig and Deeks, 2015). BzBr-FC induces a significantly lower mean IOP and exerts a more IOP reduction than either brinzolamide or brimonidine monotherapy (Katz et al., 2013; Nguyen et al., 2013; Realini et al., 2013; Aung et al., 2014). Importantly, BzBr-FC can significantly lower IOP in patients after phacoemulsification cataract surgery. The mean change in postoperative IOP at 6, 12, and 24 h was −0.12, −1.12, and −1.89 mmHg in patients treated with BzBr-FC versus +3.85, +3.46, and +0.85 mmHg in patients of the control group (Georgakopoulos et al., 2020). BzBr-FC 3 times daily exerts a significantly more IOP reduction during the nocturnal period and the entire 24-h period compared to timolol 0.05% twice daily, and IOP lowering effect during the diurnal period is similar in both treatments (Seibold et al., 2017).

Safety and AEs
BzBr-FC is security with no serious AEs and other safety variables appeared (Katz et al., 2013), which also has no significant changes in visual acuity, anterior or posterior segment examination, pachymetry, and perimeter are observed (Realini et al., 2013). The most common AEs are blurred vision, dysgeusia, ocular hyperemia, dry mouth, and eye allergy (Katz et al., 2013; Realini et al., 2013; Aung et al., 2014; Weinreb et al., 2019).

4.8 Fixed-Combination of α2-Adrenoceptor Agonists and Rho-Kinase Inhibitors

4.8.1 Fixed-Concomitant Brimonidine/Ripasudil
BrRi-FC (K-232) has been used in phase III clinical trials for the treatment of POAG and OHT since 2020. At present, no new reports on this topic are available.
(17.1%), and 55.3% of patients achieve an IOP <18 mmHg at week 8
(Alezandrini et al., 2014). BzT-FC is also more effective than BrT-FC in reducing IOP after phacoemulsification surgery, and IOP value after surgery at day 3 and 5 is −1.1 ± 2.70 and −2.19 ± 2.46 mmHg in the BzT-FC-treated patients, and −1.48 ± 2.53 and −1.72 ± 2.64 mmHg in the BrT-FC-treated patients (Balsak et al., 2018).

Multiple clinical trials reported that BrT-FC is better than DzT-FC in reducing IOP, although no statistically significant difference is found (Gulkilik et al., 2011; Feke et al., 2013; Seymenoglu et al., 2015). The side-effect profile of BrT-FC is similar to that of DzT-FC. But the incidence of the burning feeling and foreign body sensation are significantly higher in patients treated with DzT-FC (43 and 28%, respectively) than in patients treated with BrT-FC (19 and 12%, respectively) (Gulkilik et al., 2011).

4.9.5 Comparison of the Fixed Combination of Carbonic Anhydrase Inhibitors and Timolol With Carbonic Anhydrase Inhibitors and Brimonidine

A clinical trial demonstrated that BzB-FC is an effective and safe alternative β-blocker free fixed combination. A significant difference in mean morning IOP reduction is observed between DzT-FC- (7.0 ± 2.8 mmHg) and BzB-FC-treated patients (8.4 ± 1.9 mmHg) for 12 weeks, but mean afternoon IOP reduction had no significant difference (Kozobolis et al., 2017). The common reported AEs are similar after both the two treatments (Kozobolis et al., 2017).

5 TOPICAL NON-FIXED COMBINATION OF TWO AGENTS

5.1 Non-fixed Combination of Prostaglandin F2a Analogs and α-2 Agonists

5.1.1 Non-fixed Combination of Latanoprost and Brimonidine

Efficacy

An important adjunctive (two-medicine) therapy to reduce IOP is represented by the non-fixed combination therapy of brimonidine tartrate (0.1, 0.15, 0.2%) twice daily and latanoprost (0.005%) once daily (Stewart et al., 2004). A multicenter, open-label, prospective evaluation study demonstrated that the adjunctive therapy with brimonidine purite 0.15% lead to an additional mean IOP reduction from a baseline value of 5.8 mmHg (26%) at peak drug effect after the treatment with 0.005% latanoprost and 3.3 mmHg (15%) at trough drug effect after 1 month (Mundorf et al., 2007). LBr-nFC (brimonidine 0.2% and latanoprost 0.005%) exerted a mean IOP reduction to 9.0 mmHg (33.9%) compared to DzT-FC 6.5 mmHg (25.3%) at 12 weeks in patients with pigmentary and pseudoexfoliative glaucoma (Zabriskie and Netland, 2003). Importantly, brimonidine can act as a supplement to therapy also in prevention as a neuroprotective agent (Conti et al., 2021).

Safety and AEs

No serious AEs are reported, and the most common AEs are ocular allergy (n = 2; 4.7%) and foreign body sensation (n = 2; 4.7%) in LBr-nFC-treated patients (Mundorf et al., 2007). While patients treated with LBr-nFC have a higher rate of conjunctival hyperemia than LT-FC-treated patients (Stewart et al., 2004).

5.1.2 Non-fixed Combination of Travoprost and Brimonidine

Efficacy

A comparative clinical trial showed that timolol 0.5% treatment is associated with a significantly greater reduction in IOP compared with brimonidine 0.2% when added to travoprost 0.004%. The mean IOP reduction is 3.9 mmHg for timolol and 2.3 mmHg for brimonidine and the IOP reduction is 20.2 and 13.4% on day 28, respectively (Reis et al., 2006).

Safety and AEs

No systemic AEs are reported, and slight occasional conjunctival hyperemia is the only AEs in TrBr-nFC-treated patients (Reis et al., 2006).

5.2 Non-fixed Combination of Prostaglandin F2a Analogs and Carbonic Anhydrase Inhibitors

5.2.1 Non-fixed Combination of Latanoprost and Brinzolamide

Efficacy

Several randomized clinical trials reported that the non-fixed combination of latanoprost 0.005% and brinzolamide 1% exerts a better IOP reducing effect than latanoprost monotherapy (Shoji et al., 2005; Nakamoto and Yasuda, 2007; Nakano et al., 2016). A comparative study demonstrated that LBz-nFC provides a more sustained IOP lowering effect than LT-nFC. LBz-nFC reduces both daytime and nighttime IOP, whereas LT-nFC only reduced IOP during daytime, with little effect on the nighttime value (Liu et al., 2009).

Safety and AEs

LBz-nFC represents a safe and effective treatment with no serious AEs reported during the observation period (Shoji et al., 2005). No significant difference in corneal endothelial cell density, systolic, diastolic, mean blood pressures, and pulse rates is observed before and after LBz-nFC administration (Nakamoto and Yasuda, 2007; Miura et al., 2008).

5.2.2 Non-fixed Combination of Bimatoprost and Dorzolamide

Efficacy

Non-fixed combination of 0.03% bimatoprost once in the morning and 2% dorzolamide twice daily in patients with POAG exerts an additional hypotensive effect and reduces vascular resistance in the ophthalmic artery compared to bimatoprost monotherapy (Stankiewicz et al., 2010; Stankiewicz et al., 2011). However, BiDz-nFC led to a significantly greater reduction in IOP compared to bimatoprost 0.03% and dorzolamide 0.02% at 4:00 h time point and show a lower IOP fluctuation compared to bimatoprost 0.03% and dorzolamide 0.02% at 2:00 h time point (Stankiewicz et al., 2010).
5.3 Non-fixed Combination of β-blockers and α2-Adrenoceptor Agonists

5.3.1 Non-fixed Combination of Betaxolol and Brimonidine

**Efficacy**

Non-fixed combination of 0.2% brimonidine tartrate and 0.5% betaxolol twice per day exerts statistically greater IOP reduction than their respective monotherapies (Chi et al., 2013). A comparative clinical trial revealed that the decrease IOP rate is 13.8–21.2% in patients treated with betaxolol, 19.8%–25.5% in patients treated with brimonidine and 22.2–33.2% in patients treated with BeBr-nFC after 8-weeks treatment (Chi et al., 2013).

**Safety and AEs**

No systemic AEs or statistical significant difference are found among patients treated with BeBr-nFC and those treated with monotherapies (Chi et al., 2013). The reported AEs include ocular foreign bodies, irritation, dizziness, headache, fatigue, and dryness of the mouth and nose (Chi et al., 2013).

5.4 Non-fixed Combination of β-blockers and Carbonic Anhydrase Inhibitors

5.4.1 Non-fixed Combination of Betaxolol and Brinzolamide

**Efficacy**

DzT-FC is more effective after 24 h exposure compared to the effect of the fixed combination of 0.5% betaxolol and 1% brinzolamide, and the rate of IOP reduction is 18–24% and 14–19% in DzT-FC and BeBz-nFC-treated patients, respectively (Brubaker et al., 2000).

**Safety and AEs**

Anticipated AEs of BeBz-nFC are consistent with the AEs after betaxolol and brinzolamide monotherapy, and the incidence of systemic AEs does not increase (Brubaker et al., 2000).

5.5 Non-fixed Combination of α-2 Agonists and Carbonic Anhydrase Inhibitors

5.5.1 Non-fixed Combination of Brimonidine and Dorzolamide

**Efficacy**

A randomized, double-masked study demonstrated that the non-fixed combination of dorzolamide 2% three times per day and 0.2% brimonidine tartrate two times per day exerts a greater reduction of AH flow, and BrDz-nFC has better IOP lowering effect than dorzolamide alone and brimonidine alone (Ermis et al., 2002; Tsukamoto and Larsson, 2004). The reduction in AH flow is 28.2 ± 18.0%, 19.3 ± 22.0%, and 37.2 ± 20.6% in brimonidine, dorzolamide and BrDz-nFC-treated patients, respectively and IOP reduction is 11.6 ± 10.1%, 8.5 ± 14.1%, and 17.9 ± 16.5%, respectively (Ermis et al., 2002; Tsukamoto and Larsson, 2004). Oztürk F, et al. found that non-fixed combination of timolol maleate and dorzolamide (TDz-nFC) is more effective in lowering IOP than BrDz-nFC, and the mean IOP reduction is 6.8 and 5.6 mmHg, respectively, after 1 year of treatment (Ozturk et al., 2005).

**Safety and AEs**

The most common ocular and systemic AEs are mild and include stinging/burning, itching, conjunctival hyperemia, irritation, dry mouth, fatigue, and bitter taste. No serious AEs are reported (Ermis et al., 2002; Ozturk et al., 2005).

5.6 Non-fixed Combination of Prostaglandin F2a Analogs and Rho-Kinase Inhibitors

5.6.1 Non-fixed Combination of Latanoprost and Ripasudil

**Efficacy**

A clinical trial showed that the lowering effect of IOP exerted by LRi-nFC is superior than that exerted by latanoprost monotherapy, and mean IOP reduction in LRi-nFC and latanoprost-treated patients is 2.2 and 1.8 mmHg respectively, before instillation (9 AM) and 3.2 and 1.8 mmHg respectively, after instillation (11 AM) (Tanihara et al., 2015).

**Safety and AEs**

No new AEs are observed when ripasudil is added to latanoprost compared to the old AEs exerted by latanoprost, and conjunctival hyperemia is the most frequent AE in patients treated with LRi-nFC and ripasudil (55.9% vs 8.7%) (Tanihara et al., 2015).

5.7 Non-fixed Combination of β-blockers and Rho-Kinase Inhibitors

5.7.1 Non-fixed Combination of Timolol and Ripasudil

**Efficacy**

A clinical trial demonstrated that TRi-nFC leads to a more IOP reduction than timolol monotherapy at 9 AM (before instillation) (2.4 versus 1.5 mmHg) and 11 AM (after instillation) (2.9 and 1.3 mmHg) (Tanihara et al., 2015).

**Safety and AEs**

No new AEs are reported when ripasudil is combined with timolol compared to the old AEs exerted by timolol, and the most common AE is conjunctival hyperemia in patients treated with TRi-nFC with 65.4% compared to 5.8% in the timolol-treated patients (Tanihara et al., 2015).

5.8 Comparison of Topical Non-fixed Combination of Two Agents

Most clinical trials demonstrated that the non-fixed combination of prostaglandin F2a analogs and carbonic anhydrase inhibitors exerts a greater IOP-lowering effect than the non-fixed combination of prostaglandin F2a analogs and alpha-2 agonists, and both of them have similar systemic and ocular AEs (Konstas et al., 2005; Feldman et al., 2007). A 3-months randomized clinical trial demonstrated that 79 patients who were treated with brinzolamide and 84 patients who...
were treated with brimonidine twice-daily as adjunctive therapy to travoprost have a diurnal IOP reduction to 2.8 and 2.1 mmHg, and the reduction of diurnal IOP ≥15% is 40 and 27.8% in TrBz-nFC- and TrBr-nFC-treated patients, respectively (Feldman et al., 2007). Konstas, et al. reported that the mean diurnal IOP reduction is 2.2 mmHg in LDz-nFC-treated patients versus 2.1 mmHg in LBr-nFC-treated patients (Konstas et al., 2005). Patients treated with LBr-nFC and LBr-nFC had similar ocular and systemic AEs, while a statistically more incidence of conjunctival hyperemia and bitter taste is observed in patients treated with LDz-nFC (n = 9 and 8) than in those treated with LBr-nFC (n = 3 and 0) (Konstas et al., 2005).

6 TOPICAL FIXED COMBINATION OF THREE AGENTS

6.1 Fixed Combination of β-blockers, α-2 Adrenergic Agonists, and Carbonic Anhydrase Inhibitors

6.1.1 Fixed Combination of Dorzolamide, Timolol, and Brimonidine (Krytantek Ofteno®)

Efficacy

TDzBr-FC has been launched in Mexico since 2007 for the treatment of glaucoma and OHT, since it decreases AH production (Nocentini and Supuran, 2019; Cimolai, 2020; Ghorai et al., 2020; Shukla et al., 2020; Supuran, 2020), and increases TM and the uveoscleral outflow (Nocentini and Supuran, 2019; Cimolai, 2020; Shukla et al., 2020). PRO-122 is a preservative-free TDzBr-FC (PF-TDzBr-FC) (NIH, 2019b).

However, several clinical studies demonstrated that IOP lowering effect of PRO-122 is not inferior to Krytantek Ofteno (NIH, 2019b). And a phase III comparative study demonstrated that the crossover between PRO-122 and TDzBr-FC does not affect IOP, and the mean IOP reduction is 0.11 mmHg difference from the baseline after 60 days (Gomez-Aguayo et al., 2018; NIH, 2019b). Furthermore, an investigator-masked, crossover study demonstrated that BIT-FC once daily exerts a greater IOP lowering effect than TDzBr-FC twice daily (Garcia-Lopez et al., 2014).

Safety and AEs

The incidence of AEs is similar between PF-TDzBr-FC and TDzBr-FC-treated patients, and ocular burning is the one with the highest incidence among the eye disorders in both groups (Gomez-Aguayo et al., 2018; NIH). The cup/disk ratio and visual field are not statistically different in BIT-FC and TDzBr-FC-treated patients (Garcia-Lopez et al., 2014).

6.2 Fixed Combination of Prostaglandin F2a Analogs, β-blockers, and α-2 Adrenergic Agonists

6.2.1 Fixed Combination of Bimatoprost, Timolol, and Brimonidine

Efficacy

Two comparative clinical studies demonstrated that TBiBr-FC has clinically and statistically significantly superior IOP lowering effects than BrT-FC (Hartleben et al., 2017; Belfort et al., 2020). A phase 3 study conducted in Mexico and Colombia revealed that the mean IOP changes from baseline are 10.03 and 9.18 mmHg, and percentage of IOP ≤13 mmHg is 33.7 and 14.8% for TBiBr-FC and BrT-FC respectively, after 12 weeks (Hartleben et al., 2017). Another phase III study conducted in Brazil demonstrated that the mean IOP reduction at 12 weeks is 10.45 mmHg in patients treated with TBiBr-FC, and 8.28 mmHg in those treated with BrT-FC. A total of 28.9, 36.8, and 71.1% of patients treated with TBiBr-FC achieved levels of IOP ≤13, ≤14, and ≤16 mmHg compared to 15.7, 22.9, and 55.4% in patients treated with BrT-FC (Belfort et al., 2020). TBiBr-FC maybe a new promising fixed-combination three agents for patients whose IOP cannot be adequate by combination two agents, but more clinical trials are needed to verify the effectiveness and safety.

Safety and AEs

The most common AEs are ocular side effects and none are serious in TBiBr-FC and BrT-FC-treated patients (Hartleben et al., 2017; Belfort et al., 2020). The most common AEs include conjunctival hyperemia, eye irritation, allergic blepharitis, allergic conjunctivitis, and dry eye. Conjunctival hyperemia, eye irritation, and eye pruritus are statistically significant in patients treated with TBiBr-FC than those treated with BrT-FC (Hartleben et al., 2017; Belfort et al., 2020).

7 TOPICAL NON-FIXED COMBINATION OF THREE AGENTS

7.1 Non-fixed Combination of Prostaglandin F2a Analogs, β-blockers, and α-2 Adrenergic Agonists

7.1.1 Non-fixed Combination of Brimonidine, Timolol, and Travoprost

Efficacy

A clinical trial demonstrated that BzT-FC plus travoprost 0.004% (TBzTr-nFC) has a greater efficacy in late afternoon and during night and better 24-h IOP control than the one exerted by TBzTr-nFC (Konstas et al., 2013a). The reduction of 24-h IOP is 3.0 mmHg (14%) exerted by TBzTr-nFC and 2.1 mmHg (10%) exerted by TBzTr-nFC. TBzTr-nFC decreases IOP better than TBzTr-nFC at all the 3 selected time points (18:00, 22:00, and 02:00), with differences ranging from 1.0 to 1.8 mmHg, and no difference is observed among the other 3 time points (06:00, 10:00, and 14:00) (Konstas et al., 2013a).

Safety and AEs

The ocular and systemic AEs are more frequently reported after the use of the non-fixed combination of three agents compared with travoprost monotherapy (Konstas et al., 2013a). Transient blurred
vision occurred significantly more frequently in TBzTr-nFC-treated patients than in those treated with BzT-FC. The incidence of itchiness, hyperemia, and fatigue are more in the TBrTr-nFC-treated patients, and other AEs were similar in the two treatments (Konstas et al., 2013a).

### 7.1.2 Non-fixed Combination of Brimonidine, Timolol and Latanoprost

#### Efficacy

A 12-weeks, randomized, multicenter study demonstrated that LTBr-nFC exerts a greater IOP lowering effect than LT-nFC in patients whose IOP is not adequately controlled by latanoprost 0.005% alone (Fechtner et al., 2011). The results showed an additional IOP reduction of 8.3 mmHg (35.5%) and 6.2 mmHg (27.0%) at 10 am, the incidence of IOP less than 18 mmHg at both peak and trough measurements is 59.6% versus 42.6%, and IOP reduction over 20% is 72.3 and 57.5% in LTBr-nFC and LT-nFC-treated patients, respectively (Fechtner et al., 2011).

#### Safety and AEs

No statistically significant difference in overall AEs is found between patients treated with LTBr-nFC and LT-nFC, and the most common AEs are ocular allergy in the patients treated with LTBr-nFC (3.9%) and punctate keratitis in those treated with LT-nFC (2.9%) (Fechtner et al., 2011).

### 7.2 Non-fixed Combination of Prostaglandin F2a Analogs, β-blockers, and Carbonic Anhydrase Inhibitors

#### 7.2.1 Non-fixed Combination of Brinzolamide, Timolol and Travoprost

#### Efficacy

Brinzolamide 1% twice daily plus TrT-FC (TBrTr-nFC) has a better IOP lowering effect than TrT-FC once daily (Hollo and Kothy, 2008; Goldberg et al., 2012). Goldberg I, et al. reported that brinzolamide reduces IOP by 1.1–1.5 mmHg (6–9%) when added to TrTFC, and an additional IOP reduction is observed at diurnal IOP, specifically at 08:00 and 16:00 o’clock (Goldberg et al., 2012). Another comparative study demonstrated that the average decrease of diurnal IOP is 6.2 mmHg (21.8%) after the use of travoprost, 9.3 mmHg (32.6%) after the use of TrT-FC, and 11.2 mmHg (39.3%) after the use of TBrTr-nFC (Hollo and Kothy, 2008).

#### Safety and AEs

No serious AEs are reported during the study (Hollo and Kothy, 2008) and common AEs including conjunctival hyperemia, eyelashes, cataract, blurring, superficial punctate keratitis, conjunctival redness, reduced visual acuity, and itching are no statistically different between patients treated with TBrTr-nFC and those treated with TrT-FC (Hollo and Kothy, 2008).

#### 7.2.2 Non-fixed Combination of Dorzolamide, Timolol and Latanoprost

#### Efficacy

Most clinical studies reported that triple non-fixed combination therapy of 2% dorzolamide, 0.5% timolol, and 0.002% latanoprost has a superior IOP lowering effect (Akman et al., 2005; Lesk et al., 2008; Hatanaka et al., 2010; Konstas et al., 2017). Konstas AG, et al. found that LTDz-nFC protects IOP from fluctuation and further more IOP reduction than latanoprost, DzT-FC, and LT-FC, with a mean 24 h-IOP of 22.1 mmHg, 19.9 mmHg, 19.5 mmHg, and 16.5 mmHg, and a IOP fluctuation of 4.7 mmHg, 4.4 mmHg, 4.1 mmHg, and 3.6 mmHg in latanoprost, DzT-FC, LT-FC, and LTDz-nFC-treated patients (Konstas et al., 2017). A 4-weeks, open-label controlled clinical trial demonstrated that the mean baseline diurnal IOP is 14.44 ± 3.03 mmHg in patients treated with LTDz-nFC, which was significantly lower than that in patients treated with latanoprost monotherapy (15.60 ± 3.09 mmHg) (Hatanaka et al., 2010). Another nonrandomized interventional study revealed that the mean IOP decrease is 6.3 and 5.8 mmHg in LTDz-nFC and DzT-FC-treated patients, respectively, and the rate of IOP reduction >20% is 66.4 and 52.9% respectively, after 12 weeks (Lesk et al., 2008). Akman A, et al. found that IOP lowering effect of latanoprost 0.005% and brimonidine 0.2% as adjunctive therapies to TDz-FC is comparable (Akman et al., 2005); the mean reduction of peak/trough IOP is 5.2/3.5 mmHg after LTDz-nFC treatment and 4.6/2.9 mmHg after TBrDz-nFC treatment, and the rate of the peak/trough IOP reduction over 15% is 77.1%/40 and 77.7%/41.7%, respectively (Akman et al., 2005).

#### Safety and AEs

LTDz-nFC provides a safety profile consistent with that of its individual components. The majority of AEs are mild or moderate (Lesk et al., 2008), and includes burning/stinging, superficial punctate keratitis, watering, itchiness, conjunctivitis hyperemia, dry eye, ocular irritation, dry mouth, foreign body sensation, and blurred vision (Konstas et al., 2008).

#### 7.2.3 Non-fixed Combination of Dorzolamide, Timolol and Tafluprost

#### Efficacy

A comparative, crossover study demonstrated that PF-tafluprost 0.0015% plus DzT-FC was compared to PF-tafluprost and latanoprost monotherapies, and PF-TDzTf-nFC is statistically and clinically more effective than both the compounds used as monotherapy. The daytime/nighttime IOP is lower in PF-TDzTf-nFC-treated patients (17.0/17.6 mmHg) than in PF-tafluprost-treated patients (2.3/2.15 mmHg) and latanoprost monotherapy-treated patients (22.3/22.1 mmHg). However, PF-tafluprost (3.9 ± 1.3 mmHg) exerts a lower 24-h IOP fluctuation compared to PF-TDzTf-nFC (4.4 ± 2.3 mmHg) and latanoprost (4.6 ± 1.6 mmHg) (Konstas et al., 2017).

#### Safety and AEs

The rates of AEs in PF-TDzTf-nFC and latanoprost-treated patients are similar, and they are more were than those in PF-tafluprost-treated patients. Burning (6.9%), stinging (20.9%), and bitter taste (11.6%) are significantly more common in patients...
treated with PF-TDzTF-nFC than in those treated with PF-taluprost monotherapy (Konstas et al., 2017).

7.2.4 Comparison of Non-fixed Combination of Prostaglandin F2a Analog, β-blockers, and Carbonic Anhydrase Inhibitors

When patients received brinzolamide 1% (2 times a day) or dorzolamide 1% (3 times a day) plus a fixed combination therapy of latanoprost and a BB, the mean IOP reduction is 1.9 and 1.8 mmHg at week 8, respectively (Tsukamoto et al., 2005). The common AEs observed in this study include ocular irritation and blurred vision. Dorzolamide causes more intense ocular irritation than brinzolamide (74% vs 16%), and no significant difference in blurred vision is observed between the two groups (52% vs 37%) (Tsukamoto et al., 2005).

Both brinzolamide and dorzolamide added to a fixed-combination latanoprost-β-blockers show a similar IOP lowering effect, but brinzolamide (2 times a day) presents a better patient compliance and ocular comfortable than dorzolamide (3 times a day), which is more meaningful for glaucoma patients.

7.3 Non-fixed Combination of Prostaglandin F2a Analog, α-2 Adrenergic Agonists and Carbonic Anhydrase Inhibitors

7.3.1 Non-fixed Combination of Brinzolamide, Brimonidine and Travoprost

Efficacy

A phase 4 clinical trial involving 233 patients randomly treated with BzBr-FC 3 times per day plus travoprost 0.004% once daily (BzBrTr-nFC) or vehicle plus travoprost 0.004% for 6 weeks revealed that the mean diurnal IOP change from travoprost-treated baseline is significant more in BzBrTr-nFC-treated patients (5.0 mmHg, 21.9%) than in travoprost-treated patients (2.0 mmHg, 8.8%) (Feldman et al., 2016).

Safety and AEs

The incidence of AEs is higher in patients treated with BzBrTr-nFC compared to those treated with travoprost (30.8% 14.7%), and the most common AE in BzBrTr-nFC group is conjunctival hyperemia (Feldman et al., 2016).

7.3.2 Comparison of Non-fixed Combination of Prostaglandin F2a Analog, α-2 Adrenergic Agonists, and Carbonic Anhydrase Inhibitors

Several clinical trials reported that BzBr-FC as an adjunct to PGA exerts an additional IOP lowering effect (Feldman et al., 2016; Topouzis et al., 2021). The percentage of mean IOP reduction is 24.7% in patients treated with BzBr-FC plus PGA and 8.2% in those treated with vehicle plus PGA at week 6 (Feldman et al., 2016). 60.0% of patients achieving the goal of IOP ≤18 mmHg after BzBr-FC plus PGA treatment versus 20.7% of patients treated with vehicle plus PGA (Topouzis et al., 2021).

AEs in BzBr-FC plus PGA-treated patients (23.2%) are higher than those in patients treated with PGA (4.3%) (Topouzis et al., 2021), but it’s perfectly acceptable. The highest incidence of ocular and non-ocular AEs occurring in patients treated with BzBr-FC plus PGA are ocular hyperemia (5.3%) and dry mouth (5.3%) (Topouzis et al., 2021). The other common AEs include eye irritation, eye pruritus, and ocular hyperemia (Topouzis et al., 2021).

8 DISCUSSION AND OPINION

Nowadays, multiple classes of topical eye drops are available for the treatment of glaucoma, but it is still a challenge to establish the most reasonable and optimal prescription for every patient because systematically extensive clinical studies on different classes of medications are still limited. In this review, the most recent articles on topical anti-hypertensive ophthalmic agents and their characteristics were summarized, which will provide a reference for glaucoma patient care. Monotherapy is usually used for initial treatment, which cannot usually reduce IOP to a physiologically level for long time. Therefore, combination multiple agents play a vital role for long-term control of IOP. Fixed combination and non-fixed combination of two agents results in similar IOP-lowering effect, which are also superior to monotherapy, and no significant difference in local and systemic AEs was observed among them. If combination two agents fail to reduce IOP sufficiently, the second drug can be replaced or a third medication can be added to the fixed combination, or a fixed-combination of three agents can be used. Now, fixed combination three agents, such as TDzBr-FC, cannot be widely available in various countries due to its obvious increase of AEs and no significant improvement in IOP, and TBIrBr-FC is still being in clinical trial. Research and development of new, reliable, effective and safe fixed combination three agents is a trend of great importance. Netarsudil is a new launched Rho-kinase inhibitor, which provides a better neuroprotection effect superior to other eye drops. Rho-kinase inhibitors might be combined with β-blockers and be suitable for those who are not candidates for PGAs. Furthermore, another potential fixed combination including latanoprost, netarsudil and timolol, may provide better IOP lowering effect and patient compliance, lower preservative exposure and the incidence of side effects by targeting more mechanisms with once per day comparing to traditional marketed medicines.

The current review revealed that the use of a fixed combination of topical anti-hypertensive ophthalmic agents is recommended as early as possible in patients with glaucoma, to better control its development and decrease the damage of the optic nerve. Fixed combination agents not only provide a better effect than monotherapy but also result in a better convenience and tolerance, and less AEs and ocular discomfortable than non-fixed combination. Apart from the effect and safety, local availability and costs are also important factors to consider. Thus, fixed combination agents are a promising choice in the treatment of glaucoma and ocular hypertension.

9 CONCLUSION

Glaucoma is still one of the most common causes of irreversible vision loss, and the reduction and control of IOP are necessary to
decrease the rate of visual field deterioration to treat glaucoma. Despite numerous surgical approaches and classes of IOP-lowering drugs available, glaucoma remains a challenging chronic disease. Many new emerging strategies including medicines and surgery are developed for the treatment of glaucoma by affecting different pathways, providing a new choice to patients and offering additivity and complementary to current therapeutics, although they need long-term rigorous verification of safety and efficacy. The current recent studies revealed that fixed combination therapy with reliable safety and effectiveness is significantly important for patients with glaucoma and effective on glaucoma, and it’s of great importance to develop fixed combination agents with a high effect for a better control of glaucoma.

AUTHOR CONTRIBUTIONS

TZ and QJ designed and revised this manuscript. TW wrote the manuscript. LC polished language in English. All of the authors have read and approved the final manuscript.

REFERENCES

Abegão Pinto, L., Vandewalle, E., Gerlier, L., Stalmans, I., and Cosopt, U. D. S. S. G. (2014). Improvement in Glaucoma Patient Quality of Life by Therapy Switch to Preservative-free Timolol/dorzolamide Fixed Combination. *Ophthalmologica* 231 (3), 166–171. doi:10.1159/000356468

Addis, V. M., and Miller-Ellis, E. (2018). Latanoprostene Bunod Ophthalmic Solution 0.024% in the Treatment of Open-Angle Glaucoma: Design, Development, and Place in Therapy. *Clin. Ophthalmol.* 12, 2649–2657. doi:10.2147/OPTH.S156038

Aihara, M., Adachi, M., Matsu, H., Togano, T., Fukuuchi, T., Sasaki, N., et al. (2017). Additive Effects and Safety of Fixed Combination Therapy with 1% Brinzolamide and 0.5% Timolol versus 1% Dorzolamide and 0.5% Timolol in Prostaglandin-Treated Glaucoma Patients. *Acta Ophthalmol.* 95 (8), e720–e726. doi:10.1111/aos.13401

Aihara, M., Lu, F., Kawata, H., Iwata, A., Liu, K., Odani-Kawabata, N., et al. (2019). Phase 2, Randomized, Dose-Finding Studies of Omidenepeg Isopropyl, a Selective EP2 Agonist, in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. *J. Glaucoma* 28 (5), 375–385. doi:10.1097/IJO.0000000000001221

Aihara, M., Lu, F., Kawata, H., Iwata, A., Odani-Kawabata, N., and Shams, N. K. (2020a). Omidenepeg Isopropyl versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study. *Am. J. Ophthalmol.* 220, 53–63. doi:10.1016/j.joal.2020.06.003

Aihara, M., Rope, A., Lu, F., Kawata, H., Iwata, A., Odani-Kawabata, N., et al. (2020b). Intraocular Pressure-Lowering Effect of Omidenepeg Isopropyl in Latanoprost Non-/low-responder Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: the FUJI Study. *Jpn. J. Ophthalmol.* 12, 2649–2657. doi:10.1159/000356468

Akman, A., Geyikkaya, A., Akova, Y. A., and Ertan, A. (2005). Comparison of the Effects on Choroidal Thickness of Bimatoprost 0.03% versus a Fixed Combination Travoprost/Timolol in Patients with Open-Angle Glaucoma or Ocular Hypertension Previously on Brimonidine/Timolol Fixed Combination. *Cutan. Ocul. Rev.* 9 (4), 397–403. doi:10.1016/S1232-014-0145-5

Angeli, A., and Supuran, C. T. (2019). Prostaglandin Receptor Agonists as Antiglaucoma Agents (A Patent Review 2013 - 2018). *Expert Opin. Ther. Pat* 29 (10), 793–803. doi:10.1080/13546878.2019.1661992

Aptel, F., and Denis, P. (2011). Balancing Efficacy and Tolerability of Prostaglandin Analogues and Prostaglandin-Timolol Fixed Combinations in Primary Open-Angle Glaucoma. *Curr. Med. Res. Opin.* 27 (10), 1949–1958. doi:10.1185/03007995.2011.613923

Asrani, S., Bacharach, J., Holland, E., Mckee, H., Sheng, H., Lewis, R. A., et al. (2020). Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. *Adv. Ther.* 37 (4), 1620–1631. doi:10.1007/s12325-020-01277-2

Asrani, S., Robin, A. L., Serle, J. B., Lewis, R. A., Usner, D. W., Kopczynski, C. C., et al. (2019). Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. *Am. J. Ophthalmol.* 207, 248–257. doi:10.1016/j.joal.2019.06.016

Aung, T., Laganovska, G., Hernandez Paredes, T. J., Branch, J. D., Tsorbatzoglou, A., and Goldberg, I. (2014). Twice-daily Brinzolamide/brimonidine Fixed Combination versus Brinzolamide or Brimonidine in Open-Angle Glaucoma or Ocular Hypertension. *Ophthalmology* 121 (12), 2348–2355. doi:10.1016/j.ijjoal.2014.04.022

Babic, N., Andrevic, V., Miljkovic, A., Grkovic, D., and Jovanovic, P. (2013). Comparison of the Efficacy and Safety of Fixed Combination Traboprost/ timolol and Dorzolamide/timolol in Patients with Primary Open-Angle Glaucoma and Ocular Hypertension. *Srps Arh Celok Lek* 141 (7–8), 441–446. doi:10.2298/srarh1308441b

Babic, N. (2015). Fixed Combinations of Glaucoma Medications. *Srp Arh Celok Lek* 143 (9–10), 626–631. doi:10.2298/srarh1510626b

Balsak, S., Kaydu, A., Erdem, S., Fuat Alakus, M., and Ozkurt, Z. G. (2018). Brimonidine-timolol versus Brinzolamide-Timolol for Treatment of Elevated Intraocular Pressure after Phacoemulsification Surgery. *Int. Ophthalmol.* 38 (4), 1583–1589. doi:10.1007/s10792-017-0626-x

Bejan-Angoulvant, T., and Angoulvant, D. (2020). Update on Beta Blockers in Open-Angle Glaucoma. *Adv. Ther.* 37 (4), 397–403. doi:10.1007/s12325-020-01277-2

Belfort, R., Jr., Paula, J. S., Lopes Silva, M. J., Della Paolera, M., Kim, T., Chen, M. Y., et al. (2020). Fixed-combination Bimatoprost/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil. *Clin. Ther.* 42 (2), 263–275. doi:10.1016/j.clinthera.2019.12.008

Berlin, M. S., Rowe-Rendleman, C., Ahmed, I., Ross, D. T., Fujii, A., Ouchi, T., et al. (2016). EP3/FP Dual Receptor Agonist ONO-9054 Administered Morning or Evening to Patients with Open-Angle Glaucoma or Ocular Hypertension: Results of a Randomised Crossover Study. *Br. J. Ophthalmol.* 100 (6), 843–847. doi:10.1136/bjophthalmol-2015-307000

Berrino, E., and Supuran, C. T. (2019). Rho-kinase Inhibitors in the Management of Glaucoma. *Expert Opin. Ther. Pat* 29 (10), 817–827. doi:10.1080/13546878.2019.1670812

Bhattacharjee, S. A., Murnane, K. S., and Banga, A. K. (2020). Transdermal Delivery of Breakthrough Therapeutics for the Management of Treatment-Resistant and post-partum Depression. *Int. J. Pharm.* 591, 120007. doi:10.1016/j.ijpharm.2020.120007

Bourne, R. R. A., Karanranta, K., Lorentz, K., Traverso, C. E., Vuorinen, I., and Rope, A. (2019). Changes in Ocular Signs and Symptoms in Patients Switching from Bimatoprost-Timolol to Tafluprost-Timolol Eye Drops: an Open-Label Phase IV Study. *BMJ Open* 9 (4), e024129. doi:10.1136/bmjopen-2018-024129

Brubaker, R. F., Ingram, C. J., Schoff, E. O., and Nau, C. R. (2000). Comparison of the Efficacy of Betaxolol-Brinzolamide and Timolol-Dorzolamide as Suppressors of Aqueous Humor Flow in Human Subjects. *Ophthalmology* 107 (2), 283–287. doi:10.1016/s0144-8069(00)00445-5

Carradori, S., Mollica, A., De Monte, C., Ganese, A., and Supuran, C. T. (2015). Nitric Oxide Donors and Selective Carbonyl Anhydrase Inhibitors: a Dual Pharmacological Approach for the Treatment of Glaucoma, Cancer and
Osteoporosis. *Molecules* 20 (4), 5667–5679. doi:10.3390/molecules20045667

Cavet, M. E., and DeCory, H. H. (2018). The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostone Bunod: Review of Nonclinical Studies. *J. Ocul. Pharmacol. Ther.* 34 (1-2), 52–60. doi:10.1089/jop.2016.0188

Chamard, C., Villain, M., Bron, A., Causse, A., Bentaleb, Y., Pelen, F., et al. (2020). Prevalence of Unknown Ocular Hypertension, Glaucoma Suspects, and Glaucoma in Patients Seen in an Ophthalmology Center in France. *Ophthalmic Res.* 63 (3), 295–301. doi:10.1159/000405417

Chen, W., Yang, X., Fang, J., Zhang, Y., Zhu, W., and Yang, X. (2020). Rho-Kinase Inhibitor A2B Adenosine Receptor: A Focus on Agonist Binding. *Molecules* 22 (3). doi:10.3390/molecules22030449

Chimolni, N. (2020). A Review of Neuropsychiatric Adverse Events from Topical Ophthalmic Brimonidine. *Hum. Exp. Toxicol.* 39 (10), 1279–1290. doi:10.1177/0960372719018307

Conlon, R., Saheb, H., and Ahmed, II (2017). Glaucoma Treatment Trends: a Review. *Acta Ophthalmol.* 95, 103557. doi:10.1111/aos.13862

Dikopf, M. S., Vajaranant, T. S., and Edward, D. P. (2017). Topical Treatment of Drug-Naı̇ve Open-Angle Glaucoma Patients. *Drug Des. Devel Ther.* 11, 302. doi:10.2147/DDDT.S80338

Fechtier, R. D., Harasymowycz, P., Nixon, D. R., Vold, S. D., Zaman, F., Williams, J. M., et al. (2011). Twelve-week, Randomized, Multicenter Study Comparing a Fixed Combination of Brimodine-Timolol with Timolol as Therapy Adjunctive to Latanoprost. *Clin. Ophthalmol.* 5, 945–953. doi:10.2147/OPHT.S19999

Fechtier, R. D., Myers, J. S., Hubatsch, D. A., Budenz, D. L., and DuBiner, H. B. (2016). Ocular Hypotensive Effect of Fixed Combination Brinzolamide/brimonidine Adjunctive to a Prostaglandin Analog: a Randomized Clinical Trial. *Eye (Lond)* 30 (10), 1343–1350. doi:10.1038/eye.2016.126

Feke, G. T., Rhee, D. J., Turalba, A. V., and Pasquale, L. R. (2013). Effects of Dorzolamide-Timolol and Brimonidine-Timolol on Retinal Vascular Autoregulation and Ocular Perfusion Pressure in Primary Open Angle Glaucoma. *J. Ocul. Pharmacol. Ther.* 29 (7), 659–645. doi:10.1089/jop.2012.0271

Feldman, R. M., Katz, G., McMeneny, M., Hubatsch, D. A., and Realini, T. (2016). A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004. *Am. J. Ophthalmol.* 165, 188–197. doi:10.1016/jajo.2016.02.026

Feldman, R. M., Tanna, A. P., Gross, R. L., Chuang, A. Z., Baker, L., Reynolds, A., et al. (2007). Comparison of the Ocular Hypotensive Efficacy of Adjunctive Brimonidine 0.15% or Brinzolamide 1% in Combination with Travoprost 0.004%. *Ophthalmology* 114 (7), 1248–1254. doi:10.1016/j.ophtha.2007.03.012

Feinberg, P., and Rossetti, L. (2011). Medical Treatment of Glaucoma: Present and Future. *Expert Opin. Investig. Drugs* 20 (7), 947–959. doi:10.1517/1471-4215-14-161

García-López, A., Pazcika, J. A., Jiménez-Román, J., and Hartleben, C. (2014). Efficacy and Tolerability of Fixed Combination Bimatoprost/timolol versus Fixed Combination Dorzolamide/brimonidine/timolol in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: a Multicenter, Prospective, Crossover Study. *BMC Ophthalmol.* 14, 161. doi:10.1186/1471-2415-14-161

García-Medina, J. J., Rubio-Velazquez, T., Lopez-Bernal, M. D., Cobo-Martinez, A., Zanon-Moreno, V., Pinazo-Duran, M. D., et al. (2020). Glaucoma and Antioxidants: Review and Update. *Antioxidants (Basel)* 9 (11). doi:10.3390/antiox911031

Georgakopoulos, C. D., Kagkelaris, K., Pagoulatos, D., Plots, P., and Makri, O. E. (2020). Brinzolamide-brimonidine Fixed Combination for the Prevention of Intraocular Pressure Elevation after Phacoemulsiﬁcation. *Eur. J. Ophthalmol.* 30 (2), 293–298. doi:10.1177/1120672118817997

Georgakopoulos, C. D., Makri, O. E., Plots, P., and Pharmacakis, N. (2013). Brinzolamide-timolol Fixed Combination for the Prevention of Intraocular Pressure Elevation after Phacoemulsiﬁcation. *Clin. Exp. Ophthalmol.* 41 (6), 662–667. doi:10.1111/ceo.12092

Ghorai, S., Pulya, S., Ghosh, K., Panda, P., Ghosh, B., and Gayen, S. (2020). Structure-activity Relationship of Human Carbonic Anhydrase-II Inhibitors: Detailed Insight for Future Development as Anti-glaucoma Agents. *Bioorg. Chem.* 95, 103557. doi:10.1016/j.bioorg.2019.103557

Goel, M., Picciani, R. G., Lee, R. K., and Bhattacharya, S. K. (2010). Aqueous Humor Dynamics: a Review. *Open Ophthalmol. J.* 4, 52–59. doi:10.2174/187436101004010052

Goldberg, I., Crowston, J. G., Jasek, M. C., Stewart, J. A., Stewart, W. C., and Group, A. S. I. (2012). Intraocular Pressure-Lowering Efficacy of Brinzolamide when Added to Travoprost/timolol Fixed Combination as Adjunctive Therapy. *J. Glaucoma* 21 (1), 55–59. doi:10.1097/IGJ.0b013e3181f8c842

Gómez-Aguayo, F., Pazzca, J. A., Lebero-Córdoa, R., Jiménez-Román, J., Davila-Villareal, J., Hartleben, C., et al. (2018). A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma. *Clin. Ophthalmol.* 7 (1), 145–156. doi:10.2147/OPTH.S123218-018-0128-8

Greig, S. L., and Deeks, E. D. (2015). Brinzolamide/brimonidine: a Review of its Use in Patients with Open-Angle Glaucoma or Ocular Hypertension. *Drugs Aging* 32 (3), 251–260. doi:10.1007/s40266-015-0250-4
Pinnock, C., Yip, J. L., Khawaja, A. P., Luben, R., Hayat, S., Broadway, D. C., et al. (2016). Topical Beta-Blockers and Cardiovascular Mortality: Systematic Review and Meta-Analysis with Data from the EPIC-Norfolk Cohort Study. *Ophthal. Epidemiol.* 23 (5), 277–284. doi:10.1080/09282656.2016.1213301

Qiu, T. G. (2021). Trabodenoson on Trabecular Meshwork Rejuvenation: a Comprehensive Review of Clinical Data. *Expert Opin. Investig. Drugs* 30 (3), 227–236. doi:10.1080/13543776.2021.1873276

Razeghinejad, M. R., and Lee, D. (2019). Managing normal Tension Glaucoma by Reduction in Intraocular Pressure and Ocular Perfusion Pressure. *Invest. Ophthalmol. Vis. Sci.* 23 (5), 277–284. doi:10.1080/13543776.2021.1873276

Sezgin Akçay, B. (2019). Therapeutic Use of Carbonic Anhydrase Inhibitors. *Subcell. Biochem.* 75, 349–359. doi:10.1007/978-3-319-67359-2_17

Selbod, L. K., DeWitt, P. E., Kroehl, M. E., and Kahook, M. Y. (2017). The 24-Hour Effects of Brinzolamide/Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure. *J. Ocul. Pharmacol. Ther.* 33 (3), 161–169. doi:10.1089/jopt.2016.0141

Serle, J. B., Katz, L. J., McLaurin, E., Heah, T., Ramirez-Davis, N., Usner, D. W., et al. (2018). Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients with Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). *Am. J. Ophthalmol.* 186, 116–127. doi:10.1016/j.ajo.2017.11.019

Seymenoglu, G., Baser, E. F., Oztürk, B., and Gaihan, C. (2015). Comparison of Dorzolamide/timolol versus Brimonidine/timolol Fixed Combination Therapy in the Management of Steroid-Induced Ocular Hypertension. *J. Glaucoma* 24 (2), 111–116. doi:10.1097/IJG.0000000000000436

Sergin Akçay, B. L., Güney, E., Bozkurt, K. T., Uluno, C., and Akca, G. (2013). The Safety and Efficacy of Brinzolamide 1%/timolol 0.5% Fixed Combination versus Dorzolamide 2%/timolol 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension. *J. Ocul. Pharmacol. Ther.* 29 (10), 882–886. doi:10.1089/jopt.2013.0102

Shedden, A., Adamson, I. A., Getson, A. J., Laurence, J. K., Lines, C. R., Hewitt, D. J., et al. (2010). Comparison of the Efficacy and Tolerability of Preservative-free and Preservative-Containing Formulations of the Dorzolamide/timolol Fixed Combination (COSOPT™) in Patients with Elevated Intraocular Pressure in a Randomized Clinical Trial. *Graefes Arch. Clin. Exp. Ophthal.alm.* 248 (12), 1757–1764. doi:10.1007/s00417-010-1397-7

Shim, S. H., Kim, J. M., Choi, C. Y., and Kim, C. Y. (2014). Diurnal Intraocular Pressure with Bimatoprost/timolol Fixed Combination versus Latanoprost/timolol Fixed Combination in Healthy Subjects. *Korean J. Ophthalmol.* 28 (1), 39–48. doi:10.3341/j.kjo.2014.28.1.39

Shoji, N., Ogata, H., Suyama, Y., Ishikawa, H., Suzuki, H., Morita, T., et al. (2005). Intraocular Pressure Lowering Effect of Brinzolamide 1.0% as Adjunctive Therapy to Latanoprost 0.005% in Patients with Open Angle Glaucoma or Ocular Hypertension: an Uncontrolled, Open-Label Study. *Curr. Med. Res. Opin.* 21 (4), 503–508. doi:10.1177/030079950528222

Shoji, T., Sato, H., Mizukawa, A., Hirota, N., Enoki, T., Kojima, T., et al. (2013). Hypotensive Effect of Latanoprost/timolol versus Travoprost/timolol Fixed Combinations in NTG Patients: a Randomized, Multicenter, Crossover Clinical Trial. *Invest. Ophthalmol. Vis. Sci.* 54 (9), 6242–6247. doi:10.1167/iovs.13-1942

Shukla, A. K., Razeghinejad, R., and Myers, J. S. (2020). Balancing Treatments for Patients with Systemic Hypertension and Glaucoma. *Expert Opin. Pharmacother.* 21 (18), 2225–2230. doi:10.1080/13543776.2020.1810235

Singh, I. P., Fechtner, R. D., Myers, J. S., Kim, T., Usner, D. W., McKee, H., et al. (2020). Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients with Open-Angle Glaucoma or Ocular Hypertension. *Lancet Neurol.* 29 (3), 278–284. doi:10.1016/S1474-4422(20)30201-5

Skrzypecki, J., Grabiska-Liberek, I., Przybek, J., and Ufnal, M. (2018). A Common Humoral Background of Intraocular and Arterial Blood Pressure Dysregulation. *Curr. Med. Res. Opin.* 34 (3), 521–529. doi:10.1177/03000799177415203

Speth, G. L., Bernstein, P., Caprioli, J., and Schiffman, R. M. (2011). Control of Intraocular Pressure and Fluctuation with Fixed Combination Brimonidine-Timolol versus Brimonidine or Timolol Monotherapy. *Am. J. Ophthalmol.* 151 (1), 93–e4. doi:10.1016/j.ajo.2010.07.024

Stankiewicz, A., Misuki-Hojlo, M., Grabiska-Liberek, I., Romanowska-Dixon, B., Wierzbowiska, J., Wysyłek, J., et al. (2011). Intraocular Pressure and Ocular Hemodynamics in Patients with Primary Open-Angle Glaucoma Treated with the Combination of Morning Dosing of Bimatoprost and Dorzolamide Hydrochloride. *Acta Ophthalmol.* 89 (1), e57–63. doi:10.1111/j.1755-3788.2010.02036.x

Stankiewicz, A., Wierzbowiska, J., Siemiatowska, A., Fuskinska, B., Robaszkiewicz, J., Zegadlo, A., et al. (2010). The Additive Effect of Dorzolamide Hydrochloride (Trusopt) and a Morning Dose of Bimatoprost (Lumigan) on Intraocular Pressure and Retrobulbar Blood Flow in Patients with Primary-Open Angle Glaucoma. *Br. J. Ophthalmol.* 94 (10), 1307–1311. doi:10.1136/bjo.2009.162859

Stewart, W. C., Stewart, J. A., Day, D. G., Sharpe, D. E., and Jenkins, J. N. (2004). Efficacy and Safety of the Latanoprost/timolol Maleate Fixed Combination vs Concomitant Brimonidine and Latanoprost Therapy. *Eye (Lond)* 18 (10), 990–995. doi:10.1038/sj.eye.6701375

Supuran, C. T., Altamimi, A. S. A., and Carta, F. (2019). Carbonic Anhydrase Inhibition and the Management of Glaucoma: a Literature and Patent Review 2013-2019. *Expert Opin. Ther. Pat.* 29 (10), 781–792. doi:10.1080/13543776.2019.1679117

Supuran, C. T. (2020). An Update on Drug Interaction Considerations in the Therapeutic Use of Carbonic Anhydrase Inhibitors. *Expert Opin. Drug Metab. Toxicol.* 16 (4), 297–307. doi:10.1080/17425255.2020.1743679

Suto, F., Rowe-Rendleman, C. L., Ouchi, T., Jamil, A., Wood, A., and Ward, C. L. (2015). A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers. *Invest. Ophthalmol. Vis. Sci.* 56 (13), 7963–7970. doi:10.1167/iovs.15-18166

---

Frontiers in Pharmacology | www.frontiersin.org 28 December 2021 | Volume 12 | Article 749658
Suzuki, G., Kunikane, E., Shinno, K., Kozai, S., Kurata, M., and Kawamura, A. (2020). Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol after Topical Application in Rabbits: Comparison between Fixed-Combination and Single Drugs. *Ophthalmol. Ther.* 9 (1), 115–125. doi:10.1007/s40123-020-00229-x

Suzuki, K., Otsuka, N., Otsuka, N., Hizaki, H., Hashimoto, M., and Kawaiama, Y. (2018). Tafufoprostaglolin Timol in Glaucoma. *J. Ophthalmol. Timol. Study, GMulticenter, Randomized, Controlled Study Comparing Tafufoprostaglolin Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.* *Adv. Ther.* 35 (6), 796–808. doi:10.1007/s12323-018-0718-9

Takagi, Y., Santo, K., Hashimoto, M., and Fukushima, T. (2018). Ocular Hypotensive Effects of Prostaglandin Analogs in Japanese Patients with normal-tension Glaucoma: a Literature Review. *Clin. Ophthalmol.* 12, 1837–1844. doi:10.2147/OPHT.S166657

Tanihara, H., Inoue, T., Yamamoto, T., Kuwayama, Y., Abe, H., Araie, M., et al. (2013). Phase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular Hypertension. *Am. J. Ophthalmol.* 156 (4), 731–736. doi:10.1016/j.ajo.2013.05.016

Tanihara, H., Inoue, T., Yamamoto, T., Kawaiama, Y., Abe, H., Fukushima, A., et al. (2016). One-year Clinical Evaluation of 0.4% Ripasudil (K-115) in Patients with Open-Angle Glaucoma and Ocular Hypertension. *Acta Ophthalmol.* 94 (1), e26–34. doi:10.1111/aos.12829

Tanihara, H., Inoue, T., Yamamoto, T., Kawaiama, Y., Abe, H., Suganami, H., et al. (2015). Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined with Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. *Jama Ophthalmol.* 133 (7), 755–761. doi:10.1001/jamaophthalmology.2015.0525

Tanna, A. P., and Johnson, M. (2018). Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension. *Ophthalmol. Ther.* 125 (11), 1741–1756. doi:10.1016/j.ophtha.2018.08.040

Terao, E., Nakakura, N., Sagata, Y., Dote, S., Tabuchi, H., and Kiiuchi, Y. (2020). Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepeg Isopropyl 0.002% and Ripasudil 0.4%. *Cureus* 12 (9), e10368. doi:10.7759/cureus.10368

Topouzis, F., Goldberg, I., Bell, K., Tatham, A. J., Ridolfo, A., Hubatsch, D., et al. (2021). Brinzolamide/brimonidine Fixed-Dose Combination Bid as an Adjunct to a Prostaglandin Analog for Open-Angle Glaucoma/ocular Hypertension. *Eur. J. Ophthalmol.* 31 (1), 103–111. doi:10.1111/j.1120672198780044

Tsukamoto, H., and Larsson, L. I. (2004). Aqueous Humor Flow in normal Human Eyes Treated with Brimonidine and Dorzolamide, Alone and in Combination. *Arch. Ophthalmol.* 122 (2), 190–193. doi:10.1001/ archoph.122.2.190

Tsukamoto, H., Noma, H., Matsuyama, S., Ikeda, H., and Mishima, H. K. (2005). The Efficacy and Safety of Topical Brinzolamide and Dorzolamide when Added to the Combination Therapy of Latanoprost and a Beta-Blocker in Patients with Glaucoma. *J. Ocul. Pharmacol. Ther.* 21 (2), 170–173. doi:10.1089/ jopt.2005.21.170

Van de Velde, S., Van Bergen, T., Sijnav, D., Hollander, K., Casternons, K., Defert, O., et al. (2014). AMA0076, a Novel, Locally Acting Rho Kinase Inhibitor, Potently Lowers Intraocular Pressure in New Zealand white Rabbits with Minimal Hyperemia. *Invest. Ophthalmol. Vis. Sci.* 55 (2), 1006–1016. doi:10.1167/iovs.13-13157

Wareham, L. K., Buys, E. S., and Sappington, R. M. (2018). The Nitric Oxide-Guanulate Cyclase Pathway and Glaucoma. *Nicot. Oxide 77, 75–87. doi:10.1016/j.niox.2018.04.010

Webb, T. E. R. (2021). A Review of Glaucoma Surgical Therapy. *Vet. Ophthalmol.* 24 Suppl 1 (Suppl. 1), 34–38. doi:10.1111/voph.12852

Weinreb, R. N., Bacharach, J., Fecther, R. D., Kahook, M. Y., Wirta, D., Burnmaster, S., et al. (2019). 24-Hour Intraocular Pressure Control with Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial. *Ophthalmolology* 126 (8), 1095–1104. doi:10.1016/j.ophtha.2018.10.040

Weinreb, R. N., Liebmann, J. M., Martin, K. R., Kaufman, P. L., and Vititow, J. L. (2016). Latanoprostene Bunod 0.024% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. *J. Glaucoma* 27 (1), 7–15. doi:10.1097/JJG.0000000000000831

Xu, C., Guo, R., Huang, D., Ji, J., and Liu, W. (2020). Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. *J. Ophthalmol.* 2020, 2406783. doi:10.1155/2020/2406783

Yang, Z., Wang, J., Li, X., Cheng, Y., Deng, L., and Zhong, Y. (2013). Y-39983 Downregulates RhoA/Rho-Associated Kinase Expression during its Promotion of Axonal Regeneration. *Oncol. Rep.* 29 (3), 1140–1146. doi:10.3892/or.2012.2205

Yavas, G. F., Kusbeci, T., Polat, O., Karadas, M., Ernis, S. S., and Inan, U. U. (2013). Comparison of Latanoprost, Brimonidine Tartrate, and Bimatoprost Plus Timolol Maleate in Fixed Combinations. *Turk. J. Med. Sci.* 43 (2), 321–325. doi:10.9069/sag.2012-404

Yu, A., and Welge-Lüßen, U. (2013). Mechanisms, Clinical Profile and Role of Prostaglandin and Prostamides Analogues in Antiglaucomatous Therapy. *Klin Monbl Augenheilk.* 230 (2), 127–132. doi:10.1055/s-0032-1327946

Zabridiskie, N., and Netland, P. A. (2003). Comparison of Brimonidine/Latanoprost and Timolol/Dorzolamide: Two Randomized, Double-Masked, Parallel Clinical TrialsComparison of Brimonidine/latanoprost and Timolol/dorzolamide: Two Randomized, Double-Masked, Parallel Clinical Trials. *Adv. Ther.* 20 (2), 92–100. doi:10.1007/BF02850256

Zhao, J. L., Ge, J., Li, X. X., Li, Y. M., Sheng, Y. H., Sun, N. X., et al. (2011). Comparative Efficacy and Safety of the Fixed versus Unfixed Combination of Latanoprost and Timolol in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension. *BMC Ophthalmol.* 11, 23. doi:10.1186/1471-2415-11-23

Zhou, X., Zhang, T., and Wu, J. (2019). Brimonidine Enhances Inhibitory Postsynaptic Activity of OFF- and ON-type Retinal Ganglion Cells in a Wistar Rat Chronic Glaucoma Model. *Exp. Eye Res.* 189, 107833. doi:10.1016/j.exer.2019.107833

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Cao, Jiang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

IOP intraocular pressure
TM trabecular meshwork
NTG normal tension glaucoma
POAG primary open-angle glaucoma
AH aqueous humor
OHT ocular hypertension
AEs adverse effects
PGs prostaglandins
PGF2 prostaglandin F2
PGE2 prostaglandin E2
OMDI omidenepag isopropyl
NO nitric oxide
sGC-cGMP soluble guanylyl cyclase/cyclic guanosine monophosphate
QD every evening
LBN latanoprostene bunod
BBs β-blockers
hCA human carbonic anhydrase
AR adenosine receptor
LT-FC fixed combination Latanoprost and Timolol
BiT-FC fixed combination Bimatoprost and Timolol
TrT-FC fixed combination of Travoprost and Timolol
BKC benzalkonium chloride
PF preservative-free
TFT-FC fixed combination of Talfluprost and Timolol
LC-FC fixed combination of Latanoprost and carteolol
LC-nFC non-fixed combination of carteolol and latanoprost
NL-FC fixed combination of Latanoprost and Netarsudil
BiBr-FC fixed combination of Bimatoprost and Brimonidine
TrBz-FC fixed combination of Travoprost and Brinzolamide
LDz-FC fixed combination of Latanoprost and Dorzolamide
BrT-FC fixed combination of Brimonidine and Timolol
BzT-FC fixed combination of Timolol and Brinzolamide
DzT-FC fixed combination of Timolol and Dorzolamide
BzBr-FC fixed combination of Brinzolamide and Brimonidine
BrRi-FC fixed-concomitant of Brimonidine and Ripasudil
LBr-nFC non-fixed combination of Latanoprost and Brimonidine
TrBr-nFC non-fixed combination of Travoprost and Brimonidine
LBz-nFC non-fixed combination of Latanoprost and Brinzolamide
BiDz-nFC non-fixed combination of Bimatoprost and Dorzolamide
BeBr-nFC non-fixed combination of Betaxolol and Brimonidine
BeBz-nFC non-fixed combination of Betaxolol and Brinzolamide
BrDz-nFC non-fixed combination of Brimonidine and Dorzolamide
LRi-nFC non-fixed combination of Latanoprost and Ripasudil
TRi-nFC non-fixed combination of Timolol and Ripasudil
TBrTr-FC non-fixed combination of Brimonidine, Timolol and Travoprost
TBiBr-FC fixed combination of Bimatoprost, Timolol, and Brimonidine
TBzTr-nFC non-fixed combination of Brinzolamide, Timolol and Travoprost
LTBr-nFC non-fixed combination of Brimonidine, Timolol and Latanoprost
LTDz-nFC non-fixed combination of Dorzolamide, Timolol and Latanoprost
TDzTf-nFC non-fixed combination of Dorzolamide, Timolol and Talfluprost.